| Disease |
| Disease |
Drug/chemo/stress |
Method |
Sample |
Expression pattern |
Dysfunction type |
Description |
PMID |
| osteoarthritis |
|
microarray,qRT-PCR |
OA and normal knee cartilage |
up-regulated |
interaction |
LncRNA H19 acts as a metabolic correlate in cartilage and cultured chondrocytes, while the miR-675 may indirectly influence COL2A1 levels. H19 may not only be an attractive marker for cell anabolism but also a potential target to stimulate cartilage recovery |
22527881 |
| ovarian cancer |
|
microarray, qRT-PCR, western blot |
cell lines (OVCAR-3, OV-90 and SK-OV-3) |
down-regulated |
interaction |
We find that overexpression of H1.3 decreases the growth rate and colony formation of OVCAR-3 cells. We identify histone H1.3 as a specific repressor for the noncoding oncogene H19. Overexpression of H1.3 suppresses H19 expression, and knockdown of H1.3 increases its expression in multiple ovarian epithelial cancer cell lines. Furthermore, we demonstrate that histone H1.3 overexpression leads to increased occupancy of H1.3 at the H19 regulator region encompassing the imprinting control region (ICR), concomitant with increased DNA methylation and reduced occupancy of the insulator protein CTCF at the ICR. Finally, we demonstrate that H1.3 overexpression and H19 knockdown synergistically decrease the growth rate of ovarian cancer cells |
25205099 |
| type 2 diabetes mellitus |
|
N/A |
muscle of human subjects with type-2 diabetes and insulin resistant rodents. |
down-regulated |
interaction |
H19 is significantly decreased in muscle of human subjects with type-2 diabetes and insulin resistant rodents. This decrease leads to increased bioavailability of let-7, causing diminished expression of let-7 targets, which is recapitulated in vitro where H19 depletion results in impaired insulin signaling and decreased glucose uptake. |
25399420 |
| colorectal cancer |
|
qRT-PCR, western blot, Luciferase reporter assay, RIP |
CRC tissue, cell lines (SW620, HCT-116) |
up-regulated |
interaction |
We found that H19 was highly expressed in mesenchymal-like cancer cells and primary CRC tissues. H19 modulated the expression of multiple genes involved in EMT by acting as a competing endogenous RNA, which may build up the missing link between the regulatory miRNA network, EMT progression and accelerates in vivo and in vitro tumor growth. |
26068968 |
| gastric cancer |
|
qRT-PCR, Luciferase reporter assays, knockdown |
gastric cancer tissue |
up-regulated |
interaction |
H19 expression was found to be inversely correlated to miR-141 expression in gastric cancer cells and tissues. H19 promotes malignancy including proliferation and invasion whereas miR-141 suppresses malignancy in human cancer cells. MiR-141 binds to H19 in a sequence specific manner, and suppresses H19 expression and functions including proliferation and invasion. MiR-141 could also regulate H19 target genes and miR-141 inhibitor restores H19 siRNA function, while H19 regulates miR-141 target gene ZEB1 |
26160158 |
| bladder cancer |
|
qRT-PCR, western blot |
bladder cancer tissue, cell lines (5637, UMUC-3, EJ) |
up-regulated |
interaction |
YAP1 and H19 expression levels were markedly elevated in bladder cancer tissues and cells, and H19 expression was found to be significantly associated with YAP1 expression. YAP1 and H19 were overexpressed were associated with poorer clinicopathologic prognosis. In addition, YAP1 was found to enhance H19 expression, whereas H19 had no significant effect on YAP1 expression in bladder cancer cells. |
26163939 |
| bladder cancer |
|
qRT-PCR, western blot, Luciferase reporter assays, knockdown |
bladder cancer tissues, cell lines (RT4, HT-1376, 5637, 253J, TCCSUP, T24, and J82) |
up-regulated |
interaction |
We found that miR-675 expression levels were remarkably increased in bladder cancer tissues as compared with adjacent noncancerous tissues or normal bladder tissue from health donors; moreover, enhanced miR-675 expression was also observed in bladder cancer cell lines. Ectopic expression of H19 significantly increased bladder cancer cell proliferation and miR-675 expression in vitro |
26198047 |
| non-small cell lung cancer |
|
qRT-PCR, Luciferase reporter assays, knockdown, ChIP |
NSCLC cell lines (A549, SPCA1) |
up-regulated |
interaction |
The higher expression of H19 was positively correlated with advanced tumor-node-metastasis (TNM) stage and tumor size. Multivariate analyses found that H19 expression could serve as an independent prognostic factor for overall survival of NSCLC. Moreover, chromatin immunoprecipitation (ChIP) assays revealed that H19 was a direct transcriptional target of c-Myc. And, knockdown of H19 significantly inhibited NSCLC cell proliferation both in vitro and in vivo. |
26482621 |
| non-small cell lung cancer |
|
qRT-PCR, luciferase reporter assay, ChIP, overexpression
|
NSCLC tissues and cells, the adjacent tissues and normal cells |
up-regulated |
interaction |
lncRNA H19, which is induced by c-Myc, is up-regulated in NSCLC. H19 influences the mitotic progression of NSCLC cell lines. |
26722426 |
| colorectal cancer |
|
|
83 CRC patients |
up-regulated |
interaction |
overexpression of H19 promoted the proliferation of CRC cells; growth regulator |
26989025 |
| nasopharyngeal carcinoma |
|
knockdown |
NPC tissues |
up-regulated |
interaction |
H19 regulated EZH2 expression suppressing the activity of miR-630 |
27040767 |
| heart disease |
|
knockdown |
C-kit(+) cardiac progenitor cells (CPCs) |
down-regulated |
interaction |
Long noncoding RNA H19 mediates melatonin inhibition of premature senescence of c-kit(+) cardiac progenitor cells by promoting miR-675. |
27062045 |
| thyroid cancer |
|
knockdown, overexpression, Dual-Luciferase Reporter assays, RNA-binding protein RNA immunoprecipitation assays, |
tumor samples and thyroid cancer cell lines |
up-regulated |
interaction |
H19 functions as a competitive endogenous RNA (ceRNA) by acting as a sink for miR-17-5p, revealing a potential ceRNA regulatory network involving H19 and miR-17-5p with a role in the modulation of YES1 expression. |
27093644 |
| fetal growth restriction |
|
knockdown |
extravillous trophoblast (EVT) cells, FGR placentae |
down-regulated |
interaction |
Dysregulation of this newly identified H19/TβR3-mediated regulatory pathway may contribute to the molecular mechanism of FGR. Our findings are the first to show a lncRNA-based mechanism of FGR, holding promise for the development of novel predictive, diagnostic, and therapeutic modalities for FGR. |
27223264 |
| renal fibrosis |
|
knockdown |
TGF-β2-induced HK-2 cell fibrosis and unilateraureteral obstruction (UUO)-induced renal fibrosis vivo. |
up-regulated |
interaction |
H19 up-regulation contributes to renal fibrosis. H19 inhibition might represent a novel anti-fibrotic treatment in renal diseases. |
27391349 |
| glioma |
|
luciferase reporter assay, Knockdown |
glioma tissues , glioma-associated endothelial cells (GEC) |
up-regulated |
interaction |
Knockdown of H19 suppressed glioma-induced endothelial cell proliferation, migration and tube formation in vitro and meanwhile up-regulated the expression of miR-29a. |
27543358 |
| non-small cell lung cancer |
|
knockdown, western blot, |
H19 stable knocking-down A549 cells. |
up-regulated |
interaction |
H19 may regulate NSCLC metastasis through modulating cellular signaling pathway proteins related to cell proliferation and cell adhesion, including MACC1, EGFR, β-catenin and ERK1/2. |
27607135 |
| glioma |
|
Knockdown |
human glioma cell lines and clinical tumor samples |
up-regulated |
interaction |
H19 might be an oncogenic lncRNA that promoted proliferation and metastasis of glioma and could be regarded as a therapeutic target in human glioma. |
27693036 |
| keloid |
|
western blotting, knockdown |
human keloids , normal scars and normal skin |
up-regulated |
interaction |
Long non-coding RNA H19 promotes the proliferation of fibroblasts in keloid scarring. |
27698867 |
| gallbladder cancer |
|
qRT-PCR, dual-luciferase reporter assays, RIP, RNA pull-down, Western-blotting, knockdown |
GBC tissues and matched normal tissues |
up-regulated |
interaction |
H19 knockdown inhibited both cells invasion and proliferation, but this effects was attenuated by co-transfection of siRNA-H19 and miR-342-3p inhibitor in GBC cells. |
27716361 |
| endometrial cancer |
|
knockdown |
endometrial cancer tissue |
up-regulated |
interaction |
Metformin acts by upregulating microRNA let-7 through AMPK activation, leading to degradation of H19 long noncoding RNA, which normally binds to and inactivates SAHH. |
27775072 |
| colorectal cancer |
|
knockdown |
colorectal cancer cell |
|
interaction |
H19 silencing blocked G1-S transition, reduced cell proliferation, and inhibited cell migration |
27789274 |
| cholangiocarcinoma |
oxidative stress |
RNA-seq, knockdown, overexpression, RIP |
CCA cell lines |
up-regulated |
interaction |
LncRNAs H19 and HULC, activated by oxidative stress, promote cell migration and invasion in cholangiocarcinoma through a ceRNA manner. |
27809873 |
| breast cancer |
paclitaxel (PTX) |
RNA-seq, |
breast cancer cells |
up-regulated |
interaction |
Altered ERα expression may therefore change H19 levels to modulate the apoptosis response to chemotherapy in breast cancer cells. Our data suggest that the ERα-H19-BIK signaling axis plays an important role in promoting chemoresistance. |
27845892 |
| tendinopathy |
|
|
tendon-derived stem cells |
up-regulated |
interaction |
Long noncoding RNA H19 accelerates tenogenic differentiation and promotes tendon healing through targeting miR-29b-3p and activating TGF-β1 signaling. |
27895107 |
| colorectal cancer |
|
qRT-PCR, knockdown |
colorectal cancer tissues |
up-regulated |
interaction |
The lncRNA H19 Promotes Cell Proliferation by Competitively Binding to miR-200a and Derepressing β-Catenin Expression in Colorectal Cancer. |
28164117 |
| glioblastoma |
|
ChIP, luciferase reporter assays |
glioblastoma cell lines U87 and U251 cells |
up-regulated |
interaction |
H19 acts as a molecular sponge that binds miR-181d, relieving inhibition of β-catenin expression. Therefore, H19 participates in hypoxia-driven migration and invasion in glioblastoma cells. |
28327666 |
| breast cancer |
|
overexpression |
human breast tumor tissues and cells |
up-regulated |
interaction |
H19 promoted proliferation and invasion of breast cancer through the miR-152/DNMT1 axis, providing a novel mechanism about the occurrence and development of breast cancer. |
28544374 |
| thyroid cancer |
|
qRT-PCR, |
TC tissues and adjacent tissues |
up-regulated |
interaction |
This study aims to explore the effects of long non-coding RNA H19 (lncRNA H19) and microRNA let7a (miRNA let7a) expression on the prognosis of thyroid cancer (TC). This may aid in the discovery of more effective treatment and prognosis approaches for TC. |
28655518 |
| acute myeloid leukemia |
|
knockdown, |
bone marrow samples from patients with AML-M2 |
up-regulated |
interaction |
Acute myelocytic leukemia (AML) is the most common type of acute leukemia. Long non-coding RNAs (lncRNAs) serve an important role in regulating gene expression through chromatin modification, transcription and post-transcriptional processing. LncRNA H19 was considered as an independent prognostic marker for patients with tumors. |
28765931 |
| non-small cell lung cancer |
|
qRT-PCR, knockdown |
tumor tissues and corresponding non-tumor lung tissues from 200 patients |
up-regulated |
interaction |
In recent years, long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have been shown to play important roles in tumor biological function. The aim of this study was to investigate the diagnostic and prognostic value of lncRNA H19 and miR-21 expression in non-small-cell lung cancer (NSCLC) |
28799568 |
| colorectal cancer |
|
qRT-PCR, |
CRC tumor tissues and adjacent normal tissues |
up-regulated |
interaction |
H19 inhibits the migration and invasiveness of CRC cells. |
29036538 |
| retinoblastoma |
|
|
retinoblastoma tissues and cell lines |
down-regulated |
interaction |
Long non-coding RNA H19 suppresses retinoblastoma progression via counteracting miR-17-92 cluster. |
29143996 |
| atherosclerosis |
|
qRT-PCR,Enzyme-linked immunosorbent assay, western blot, Luciferase reporter assay, |
Raw264.7 cells |
differential expression |
interaction |
Silencing of H19 inhibits the adipogenesis and inflammation response in ox-LDL-treated Raw264.7 cells by up-regulating miR-130b. |
29172088 |
| gastric cancer |
|
qRT-PCR |
gastric cancer tissues and cell lines |
up-regulated |
interaction |
H19 functions as a competing endogenous RNA to regulate human epidermal growth factor receptor expression by sequestering let-7c in gastric cancer. |
29207111 |
| clear cell renal cell carcinoma |
|
PCR array, qRT-PCR, dual-luciferase assay, RIP, western blot |
human clear cell renal cell carcinoma samples |
up-regulated |
interaction |
Long non-coding RNA H19 regulates E2F1 expression by competitively sponging endogenous miR-29a-3p in clear cell renal cell carcinoma. |
29214011 |
| melanoma |
|
qRT-PCR,luciferase reporterassays, MS2-RIP |
melanoma tissues |
up-regulated |
interaction |
LncRNA H19 may function as the sponge of miR-106a-5p to up-regulate E2F3 expression, and consequently promote the glucose metabolism and growth of melanoma. |
29350287 |
| ovarian cancer |
|
|
Ovarian cancer cell lines SKOV-3 and OVCAR3 |
differential expression |
interaction |
Furthermore, we demonstrated that this activity of H19 was involved in its promotion of TGF-β-induced EMT. |
29403287 |
| idiopathic pulmonary fibrosis |
|
|
|
|
interaction |
LncRNA H19 has a promotive effect on BLM-induced IPF, and it functions as a molecular sponge of miR-196a, which provides a novel therapeutic target for IPF. |
29411215 |
| spontaneous abortion |
|
qRT-PCR, western blot |
trophoblast of women with spontaneous abortion |
down-regulated |
interaction |
H19 lncRNA may regulate the expression of ZEB1. |
29559603 |
| abdominal aortic aneurysm |
|
knockdown, qRT-PCR, overexpression |
two murine AAA models, a novel preclinical LDLR-/- Yucatan mini-pig aneurysm model. |
up-regulated |
interaction |
H19 Induces Abdominal Aortic Aneurysm Development and Progression. |
29669788 |
| cardiovascular disease |
|
overexpression, knockdown, dual luciferase reporter |
mesenchymal stem cells (MSCs) |
down-regulated |
interaction |
LncRNA-H19 enhanced MSCs survival and their angiogenic potential in vitro. |
29673400 |
| non-small cell lung cancer |
|
overexpression, knockdown |
A549 and H1299 cells compared to normal lung epithelial BEAS-2B cells. |
up-regulated |
interaction |
H19 promotes non-small-cell lung cancer (NSCLC) development through STAT3 signaling via sponging miR-17. |
29693721 |
| colorectal cancer |
|
knockdown, overexpression, dual-luciferase reporter gene assay, |
HT29, HCT116, SW480 and SW620) and normal colorectal mucosa cell line (NCM460) |
up-regulated |
interaction |
The lncRNA H19/miR-29b-3p/PGRN/Wnt axis counted a great deal for seeking appropriate diagnostic biomarkers and treatment targets for CRC |
29754471 |
| lung cancer |
|
|
lung cancer cells |
down-regulated |
interaction |
LncRNA H19-elevated LIN28B promotes lung cancer progression through sequestering miR-196b |
29950144 |
| hepatocellular carcinoma |
|
qRT-PCR, western blot, Luciferase reporter gene assay, overexpression, |
HCC cell lines |
down-regulated |
interaction |
The lncRNA H19/miR-193a-3p/PSEN1 axis could be regarded as the treatment targets for HCC, so as to further improve the treatment efficacy of chemo- and radio-therapies for HCC. |
29968942 |
| endometrial carcinoma |
|
qRT-PCR, Dual luciferase reporter assay, western blot, knockdown, overexpression, |
endometrial cancer cells |
up-regulated |
interaction |
The high expression of lncRNA H19 in endometrial carcinoma thus promoting cell proliferation to play a role in the development of endometrial carcinoma. |
30070313 |
| glioblastoma |
|
overexpression |
bratumor tissue from GB patients as compared to cancer-free bratissue |
up-regulated |
interaction |
Long non-coding RNA H19, and not microRNA miR-326, is over-expressed and predicts survival in glioblastoma. |
30096248 |
| myocardial infarction |
|
|
Cardiac progenitor cells (CPCs) |
down-regulated |
interaction |
Long non-coding RNA H19 contributes to hypoxia-induced CPC injury by suppressing Sirt1 through miR-200a-3p. |
30137188 |
| dietary obesity |
|
knockdown, overexpression |
brown and white adipocytes |
down-regulated |
interaction |
LincRNA H19 protects from dietary obesity by constraining expression of monoallelic genes in brown fat. |
30190464 |
| non-small cell lung cancer |
|
Overexpression |
NSCLC tissues samples and their adjacent normal tissue samples, NSCLC cell line |
up-regulated |
interaction |
H19 contributes to poor clinical features in NSCLC patients and leads to enhanced invasion in A549 cells through regulating miRNA-203-mediated epithelial-mesenchymal transition. |
30214583 |
| breast cancer |
|
knockdown, dual-luciferase reporter assays, RNA-binding protein imunoprecipitation |
breast cancer cells |
up-regulated |
interaction |
Long noncoding RNA H19 competitively binds miR-93-5p to regulate STAT3 expression in breast cancer. |
30256448 |
| colorectal adenocarcinoma |
|
qRT-PCR, western blot, dual-luciferase reporter gene assay, knockdown, mimic |
CRA tissues |
up-regulated |
interaction |
Highly-expressed H19, lowly-expressed miR-194-5p, low-grade differentiation and lymph node metastasis appeared as the independent predictors of unfavorable prognosis in CRA patients' |
30278464 |
| non-small cell lung cancer |
|
qRT-PCR, dual-luciferase reporter gene assay, Rescue experiments, Overexpression |
NSCLC tissues, paracancerous tissues and NSCLC cell lines |
up-regulated |
interaction |
LncRNA H19 serves as a ceRNA and participates in non-small cell lung cancer development by regulating microRNA-107. |
30280776 |
| glioma |
|
qRT-PCR, Luciferase assays, RIP |
human glioma tissues and cell lines |
up-regulated |
interaction |
H19 Functions as a Competing Endogenous RNA to Regulate EMT by Sponging miR-130a-3p in Glioma |
30282068 |
| hypoxia-induced injury |
|
overexpression, knockdown, |
hypoxic Neural-like PC-12 cells, an vitro model of hypoxic bradamage. |
up-regulated |
interaction |
Protective effects of lncRNA H19 silence against hypoxia-induced injury in PC-12 cells by regulating miR-28. |
30312698 |
| thyroid cancer |
|
overexpression |
PTCSCs and PTC tissue specimens |
up-regulated |
interaction |
Estrogen receptor β upregulated by lncRNA-H19 to promote cancer stem-like properties in papillary thyroid carcinoma. |
30389909 |
| pituitary adenoma |
|
|
pituitary tumour cell |
down-regulated |
interaction |
Inhibition of mTORC1 by lncRNA H19 via disrupting 4E-BP1/Raptor interaction in pituitary tumours. |
30397197 |
| seminoma |
|
microarray |
an established cisplatin-resistant TCam-2 cell line |
up-regulated |
interaction |
H19 promotes the expression of TDRG1 by sequestering miRNA-106b-5p and uses this mechanism to facilitate cell survival in cisplatin-based chemotherapeutic conditions. |
30430771 |
| colorectal cancer |
|
Dual-luciferase reporter assay, Immunoprecipitation assay. |
increased recurrent CRC patient samples. |
up-regulated |
interaction |
Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy. |
30451820 |
| diabetes mellitus |
|
FISH, RNA-pull down, RIP, ChIP, COIP, luciferase reporter gene assay |
H19 expression fibroblasts, |
up-regulated |
interaction |
Autologous blood transfusion augments impaired wound healing in diabetic mice by enhancing lncRNA H19 expression via the HIF-1α signaling pathway. |
30458806 |
| ovarian cancer |
|
RNA-Seq, luciferase reporter assay,RIP, knockdown, overexpression |
ovarian cancer cells, Nude mice subcutaneous xenograft tumor models |
down-regulated |
interaction |
Ginsenoside 20(S)-Rg3 Prevents PKM2-Targeting miR-324-5p from H19 Sponging to Antagonize the Warburg Effect in Ovarian Cancer Cells. |
30481782 |
| myocardial ischemia/reperfusion injury |
|
overexpression, knockdown, |
cardiomyocytes exposed to oxygen-glucose deprivation and reperfusion, a mouse model of myocardial I/R |
up-regulated |
interaction |
The lncRNA H19/miR-675 axis regulates myocardial ischemic and reperfusion injury by targeting PPARα. |
30496976 |
| fetal growth restriction |
|
knockdown, |
extravillous trophoblast cells, placentae from pregnancies with FGR. |
down-regulated |
interaction |
Silencing H19 regulated proliferation, invasion, and autophagy in the placenta by targeting miR-18a-5p. |
30536700 |
| hepatocellular carcinoma |
|
qRT-PCR, knockdown, western blot, luciferase reporter assay, IHC |
HCC tissues and tissues |
up-regulated |
interaction |
LncRNA-H19 activates CDC42/PAK1 pathway to promote cell proliferation, migration and invasion by targeting miR-15b in hepatocellular carcinoma. |
30543848 |
| duchenne muscular dystrophy |
Synthetic PIF (sPIF) |
|
immune disorders and transplantation models, mouse and human myoblast |
up-regulated |
interaction |
SPIF promotes myoblast differentiation and utrophin expression while inhibiting fibrosis in Duchenne muscular dystrophy via the H19/miR-675/let-7 and miR-21 pathways. |
30692507 |
| cholestatic liver fibrosis |
|
qRT-PCR, RNA-Seq, knockdown, overexpression, RNA pull-down, RIP, |
cholestatic livers by bile duct ligation (BDL), BDL mouse livers |
up-regulated |
interaction |
H19 potentiates let-7 family expression through reducing PTBP1 binding to their precursors in cholestasis. |
30778047 |
| cardiac cancer |
|
luciferase reporter gene assay, |
cardiac cancer tissues, cardiac cancer cells |
up-regulated |
interaction |
LncRNA H19 interacted with miR-130a-3p and miR 17-5p to modify radio-resistance and chemo sensitivity of cardiac carcinoma cells. |
30843379 |
| osteoarthritis |
|
qRT-PCR, Luciferase reporter, RNA pull-down, Knockdown |
C28/I2 cells |
up-regulated |
interaction |
Knockdown of LncRNA H19 Relieves LPS-Induced Damage by Modulating miR-130a in Osteoarthritis. |
30900425 |
| corneal neovascularization |
|
|
vascularized corneas , human umbilical veendothelial cells (HUVECs) |
down-regulated |
interaction |
Long Non-coding RNA H19 Promotes Corneal Neovascularization by Targeting MicroRNA-29c. |
30948500 |
| fibrotic lung |
|
knockdown, |
human fibrotic lung tissues |
up-regulated |
interaction |
H19 knockdown attenuated pulmonary fibrosis via the regulatory network of lncRNA-H19-miR-140-TGF-β/Smad3 signaling, and H19 and miR-140 might represent potential therapeutic targets and early diagnostic and prognostic biomarkers for the patients with pulmonary fibrosis. |
30988156 |
| choriocarcinoma |
methotrexate and 5-fluorouracil |
qRT-PCR, knockout |
CC cell line |
up-regulated |
interaction |
Long noncoding RNA H19 promotes chemotherapy resistance in choriocarcinoma cells. |
31020694 |
| adipogenic differentiation. |
|
Luciferase reporter assay,knockdown |
adipose tissue-derived mesenchymal stem cells (ADSCs) |
up-regulated |
interaction |
The lncRNA H19 serves as a competing endogenous RNA (ceRNA) for miR-30a to augment miR-30a downstream target C8orf4, therefore modulating adipogenic differentiation in hADSCs. |
31026067 |
| atherosclerosis |
|
knockdown, overexpression, |
human umbilical vein endothelial cells (HUVECs) |
up-regulated |
interaction |
LncRNA H19/miR-let-7 axis participates in the regulation of ox-LDL-induced endothelial cell injury via targeting periostin. |
31054453 |
| nonalcoholic fatty liver disease |
free fatty acid (FFA) |
IHC staining, ELISA, Luciferase assay, RNA pull down, qRT-PCR, western blot, overexpression, knockdown |
liver tissue |
up-regulated |
interaction |
LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in nonalcoholic fatty liver disease. |
31064820 |
| gastric cancer |
|
overexpression, knockdown |
GC tissues and cells |
up-regulated |
interaction |
H19 was upregulated in GC tissues, which promoted tumor growth and metastasis via the miR‑22‑3p/Snail1 signaling pathway. |
31081061 |
| endometrial cancer |
|
knockdown, overexpression, mimics |
endometrial tissue, ectopic Endometriosis cell |
up-regulated |
interaction |
Down-regulation of lncRNA-H19 could inhibit ectopic endometrial cell proliferation and invasion by modulating miR-124-3p and ITGB3, offering a novel target for treatment |
31085188 |
| pancreatic neuroendocrine tumors |
|
qRT-PCR, western blot, knockdown, RIP, RNA-seq, Microarray |
pNEN tissues |
up-regulated |
interaction |
H19 is a promising prognostic factor in pNENs with malignant behaviors and functions as an oncogene via the VGF-mediated PI3K/AKT/CREB pathway. |
31117050 |
| ischemia/reperfusion injury |
|
knockout |
microglia, neuron |
up-regulated |
interaction |
LncRNA H19 initiates microglial pyroptosis and neuronal death in retinal ischemia/reperfusion injury. |
31127201 |
| lung cancer |
|
knockdown, |
lung carcinoma cell lines, lung cancer tissues |
up-regulated |
interaction |
H19 may be an epigenetic regulator of miR-6515-3p, and its dysregulation may contribute to lung cancer progression and metastasis. |
31131469 |
| ischemic brain stroke |
hypoxia |
knockdown, gain and loss of function, luciferase reported assay, RIP, pull-down |
serum of stroke patients |
up-regulated |
interaction |
Blocking lncRNA H19-miR-19a-Id2 axis attenuates hypoxia/ischemia induced neuronal injury. |
31170091 |
| arteriosclerosis obliterans |
|
overexpression, luciferase reporter gene assay, western blot |
serum, vascular endothelial cells, Human umbilical vein endothelial cells |
up-regulated |
interaction |
LncRNA H19 promotes the proliferation of vascular endothelial cells in ASO and inhibits the apoptosis of them via the NF-κB pathway. |
31173326 |
| lung cancer |
|
qRT-PCR, luciferase reporter assay,RNA pull-down, overexpression |
lung cancer tissues and cell lines |
up-regulated |
interaction |
LncRNA H19 promotes lung cancer proliferation and metastasis by inhibiting miR-200a function. |
31187349 |
| breast cancer |
|
knockdown,overexpression |
breast cancer tissues and cells |
up-regulated |
interaction |
Long non-coding RNA H19 regulates cell growth and metastasis via miR-138 in breast cancer. |
31217890 |
| non-small cell lung cancer |
hypoxia |
qRT-PCR,western blot, Luciferase assay, knockdown |
A549 and MRC-5 cells |
up-regulated |
interaction |
Upregulation of miR-675-5p induced by lncRNA H19 was associated with tumor progression and development by targeting tumor suppressor p53 in non-small cell lung cancer. |
31219199 |
| age-related cataract |
ultraviolet |
knockdown, overexpression, Luciferase assay, RNA-seq, ELISA |
Human lens epithelial cells |
up-regulated |
interaction |
lncRNA H19 contributes to oxidative damage repair in the early age-related cataract by regulating miR-29a/TDG axis |
31282110 |
| endometriosis |
|
qRT-PCR, western blot, luciferase assays |
HEK 293 cells, endometrial tissues of women with endometriosis, endometriosis euESCs, control euESCs |
down-regulated |
interaction |
Downregulation of H19 or ACTA2 inhibited endometriosis euESC invasion and migration, however estrogen promoted endometriosis euESC invasion and migration via H19. |
31323679 |
| breast cancer |
tamoxifen resistance |
qRT-PCR, Knockdown, overexpression, CHIP, immunofluorescence, western blot |
breast cancer cell line and tumor tissues |
up-regulated |
interaction |
The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy. |
31340867 |
| hyperglycemia |
high glucose, α-Mangostin |
RNA-seq |
human umbilical vein endothelial cells (HUVECs) |
down-regulated |
interaction |
H19 exerted its function via the modulation of H19/miR-140/HE4 in hyperglycemia with α-Mangostin. |
31362245 |
| pituitary adenoma |
|
overexpression, western blot, qRT-PCR, |
serum exosomal H19 |
down-regulated |
interaction |
Exosome-transmitted lncRNA H19 inhibits the growth of pituitary adenoma. |
31369093 |
| acute myeloid leukemia |
|
luciferase reporter assay, western blot |
Blood samples of 40 AML patients, AML cells |
up-regulated |
interaction |
LncRNA-H19 inhibits apoptosis of acute myeloid leukemia cells via targeting miR-29a-3p. |
31389605 |
| endometrial cancer |
|
microarray, gain- and loss-of-function experiments, knockdown |
endometrial cancer tissues |
up-regulated |
interaction |
Long noncoding RNA H19 regulates HIF-1α/AXL signaling through inhibiting miR-20b-5p in endometrial cancer. |
31411527 |
| lung adenocarcinoma |
gefitinib |
overexpression, knockdown, microarray |
gefitinib-resistant cell lines |
up-regulated |
interaction |
Long non-coding RNA H19 confers resistance to gefitinib via miR-148b-3p/DDAH1 axis in lung adenocarcinoma. |
31503013 |
| nasopharyngeal carcinoma |
|
qRT-PCR, Luciferase reporter assay, western blot, overexpression, knockdown |
nasopharyngeal carcinomas cells |
up-regulated |
interaction |
Upregulation of lncRNA H19 promotes nasopharyngeal carcinoma proliferation and metastasis in let-7 dependent manner. |
31556327 |
| endometriosis |
under Th17 differentiation conditions |
western blot, qRT-PCR, Luciferase reporter assays, ELISA, overexpression |
Peritoneal fluid of differentiated patients (pfmcs), EMS and Th17 patients |
down-regulated |
interaction |
LncRNA H19 over-expression inhibited Th17 cell differentiation to relieve endometriosis through miR-342-3p/IER3 pathway. |
31636893 |
| hepatocellular carcinoma |
|
overexpression, |
HCC tissues |
up-regulated |
interaction |
Macrophages-induced long noncoding RNA H19 up-regulation triggers and activates the miR-193b/MAPK1 axis and promotes cell aggressiveness in hepatocellular carcinoma. |
31705929 |
| multiple myeloma |
|
qRT-PCR, knockdown, western blot, Luciferase reporter assays, |
Nude mice xenograft model, MM cell |
up-regulated |
interaction |
Long non-coding RNA H19 promotes tumorigenesis of multiple myeloma by activating BRD4 signaling by targeting miR-152-3p. |
31712391 |
| diabetes mellitus |
high glucose |
|
endothelial cells |
up-regulated |
interaction |
Long Non-coding RNA H19 Suppression Protects the Endothelium Against Hyperglycemic-Induced Inflammation via Inhibiting Expression of miR-29b Target Gene Vascular Endothelial Growth Factor a Through Activation of the Protein Kinase B/Endothelial Nitric Oxide Synthase Pathway. |
31737629 |
| myocardial injury |
|
qRT-PCR, knockdown, western blot, Luciferase reporter assays, gain- and loss-of-functions assays, RIP, RNA pull-down, |
primary cardiomyocytes |
down-regulated |
interaction |
LncRNA H19 ameliorates myocardial infarction-induced myocardial injury and maladaptive cardiac remodelling by regulating KDM3A. |
31755219 |
| glioma |
|
qRT-PCR, knockdown, western blot,luciferase assay |
U373 cell lines, glioma cells |
up-regulated |
interaction |
an upregulated lncRNA H19 in glioma cells, which could promote proliferation, migration, invasion and angiogenesis via miR-138/HIF-1α axis as a ceRNA. |
31777264 |
| glaucoma |
TGF-β1 |
|
rat model of GFS, TGF-β-treated HTFs |
up-regulated |
interaction |
Role of the long noncoding RNA H19 in TGF-β1-induced Tenon's capsule fibroblast proliferation and extracellular matrix deposition. |
31877306 |
| ankylosing spondylitis |
|
Microarray,qRT-PCR,knockdown,overexpression,western blot,Luciferase reporter assays, mimics. |
Ankylosing Spondylitis cells |
up-regulated |
interaction |
H19 Increases IL-17A/IL-23 Releases via Regulating VDR by Interacting with miR675-5p/miR22-5p in Ankylosing Spondylitis. |
31887550 |
| osteoarthritis |
|
RIP,qRT-PCR,knockdown,overexpression,western blot,Luciferase reporter assays, |
OA samples from patients or cultured chondrocytes |
up-regulated |
interaction |
Long non-coding RNA H19 modulates proliferation and apoptosis in osteoarthritis via regulating miR-106a-5p. |
31894109 |
| postmenopausal osteoporosis |
BMP-2 |
qRT-PCR, western blot, mimic |
bone marrow mesenchymal stem cells |
down-regulated |
interaction |
LncRNA H19 was obviously down-regulated in postmenopausal osteoporosis patients. |
31918667 |
| keloid |
|
luciferase reporter gene assay |
80 keloid tissues, 63 normal fibrous tissues, and 91 normal skin tissues |
up-regulated |
interaction |
H19 was capable of altering miR-29a expression within fibroblasts by directly sponging it, and overexpression of COL1A1 could deter the impact of miR-29a on viability, proliferation, migration, and invasion of fibroblasts (P < .05). |
31930556 |
| cerebral ischemia/reperfusion injury |
Metformin;oxidative stress induced by ischemia/reperfusion (I/R) in vivo and oxygen glucose deprivation/reperfusion (OGD/R) in vitro. |
qRT-PCR, western blot, Luciferase reporter assays, |
Adult male C57BL/6 mice |
up-regulated |
interaction |
metformin exerts neuroprotective effects by regulating ischemic stroke-induced oxidative stress injury via the lncRNA-H19/miR-148a-3p/Rock2 axis. These results provide new evidence that metformin may represent a potential treatment for stroke-related brain injury. |
31934270 |
| hyperglycemia |
|
qRT-PCR, western blot, ELISA, Dual-luciferase reporter gene assay, RIP |
ARPE-19 cells |
down-regulated |
interaction |
H19 played an important role in regulating inflammatory processes in retinal endothelial cells under high-glucose condition through modulating miR-93/XBP1s axis. |
31953562 |
| myocardial ischemia |
H2O2 |
Knockdown, Overexpression, qRT-PCR, western blot, RIP |
mouse hearts, rat H9C2 cells |
up-regulated |
interaction |
lncRNA H19 is involved in myocardial IP via increasing the stability of nucleolin protein and lncRNA H19 may represent a potential therapeutic target for the treatment of the myocardial injury. |
31975412 |
| pre-eclampsia |
|
overexpression, knockdown, dual-luciferase reporter assay, RNA pull-down, RIP |
HTR-8/SVneo cells |
up-regulated |
interaction |
MSC-derived exosomes overexpressing H19 decreased let-7b, increased FOXO1, and activated the protein kinase B (AKT) signaling pathway, thus increasing invasion and migration and inhibiting apoptosis of trophoblast cells. |
32069774 |
| obesity-induced myocardial injury |
Ghrelin;high-fat diet (HFD) and PA treatment |
overexpression, Knockdown |
a mouse model of obesity and a palmitic acid (PA)-treated cardiomyocyte cell line with or without ghrelin transfection |
down-regulated |
interaction |
Ghrelin protects against obesity-induced myocardial injury by regulating the lncRNA H19/miR-29a/IGF-1 signalling axis. |
32084395 |
| cerebral ischemia/reperfusion injury |
glucose deprivation/reoxygenation |
Knockdown, qRT-PCR, western blot, Luciferase report assay, RIP, RNA pulldown |
PC-12 cells |
up-regulated |
interaction |
H19 promotes inflammatory response and improved neurological function in tMCAO rat model by regulating miR-138-5p and p65 expression. This study reveals the important role and underlying mechanism of H19 in the progress of cerebral I/R injury,which could serve as a potential target for further treatment. |
32114772 |
| osteoarthritis |
|
luciferase report system, qRT-PCR |
|
up-regulated |
interaction |
LncRNA H19 may promote chondrocyte proliferation and migration and inhibit matrix degradation in OA possibly by targeting the miR-106b-5p/TIMP2 axis. |
32248331 |
| melanoma |
cisplatin (DDP) |
knockdown, qRT-PCR |
melanoma tissues, cisplatin (DDP)-resistant melanoma cells |
up-regulated |
interaction |
Downregulation of lncRNA H19 sensitizes melanoma cells to cisplatin by regulating the miR-18b/IGF1 axis. |
32265386 |
| cerebral ischemia/reperfusion injury |
|
knockdown, luciferase reporter assay, western blot, qRT-PCR, overexpression |
I/R tissues and OGD/R induced cells |
up-regulated |
interaction |
LncRNA H19 Aggravates Cerebral Ischemia/Reperfusion Injury by Functioning as a ceRNA for miR-19a-3p to Target PTEN. |
32335212 |
| rheumatoid arthritis |
|
knockdown, luciferase reporter assay, western blot, immunoprecipitation, RNA pulldown |
synovial tissue from patients with RA and from mice with collagen antibody-induced arthritis (CAIA) (using Ddr2-/- and DBA/1 mice) |
|
interaction |
DDR-2 inhibition, acting through the H19-miR-103a axis, leads to reductions in the inflammatory reaction and severity of joint destruction in mice with CAIA, |
32362074 |
| bladder cancer |
|
ISH |
bladder cancer tissue etc. |
differential expression |
expression |
The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. |
11193051 |
| myeloproliferative disease polycythaemia vera |
|
N/A |
N/A |
N/A |
expression |
Expression of the imprinted tumour-suppressor gene H19 is tightly regulated during normal haematopoiesis and is reduced in haematopoietic precursors of patients with the myeloproliferative disease polycythaemia vera. |
10640993 |
| Beckwith-Wiedemann syndrome |
|
N/A |
N/A |
N/A |
epigenetics |
Mosaicism for 11p15 UPD and hypermethylation of the H19 gene in blood cells were associated with an increased risk of tumour. |
11436121 |
| hepatocellular carcinoma |
|
microarray, qRT-PCR |
HCC tissue |
up-regulated |
expression |
We found that imbalances in levels of IGF2 and H19 transcripts were correlated with advanced tumor stage and poor outcome in HCC patients. |
15736456 |
| colorectal cancer |
|
qRT-PCR |
CRC tissue |
up-regulated |
N/A |
LOI of IGF2 correlated strongly with biallelic hypermethylation of a core of five CpG sites in the insulator region of IGF2/H19, which is a known CTCF-binding element. As this methylation-dependent LOI was present in both tumors and normal colonic mucosa, it is possible that hypermethylation creates a field defect predisposing to cancer. |
11120891 |
| breast adenocarcinomas |
|
N/A |
breast adenocarcinoma stromal cells |
up-regulated |
expression |
An up-regulation of the h19 gene is significantly correlated with the tumor values and the presence of both estrogen and progesterone receptors |
9811352 |
| congenital hyperinsulinism |
|
N/A |
N/A |
N/A |
expression |
In agreement with the loss of the maternal chromosome, the level of expression of a maternally expressed tumor suppressor gene, H19, was greatly reduced compared to the level of expression of the paternally expressed growth promoter gene, IGF2. |
11395395 |
| cancer |
|
N/A |
N/A |
N/A |
expression |
The human H19 gene is frequently overexpressed in myometrium and stroma during pathological endometrial proliferative events. |
15618002 |
| lung cancer |
|
qRT-PCR |
cell lines (MCF10A, RPMI 1640, DMEM H21 etc.) |
up-regulated |
expression |
Down-regulation of H19 significantly decreases breast and lung cancer cell clonogenicity and anchorage-independent growth. In addition, c-Myc and H19 expression shows strong association in primary breast and lung carcinomas. |
16707459 |
| biparental complete hydatidiform moles |
|
N/A |
N/A |
N/A |
epigenetics |
H19 is abnormally methylated on the maternal alleles in BiCHMs. |
12783848 |
| breast cancer |
|
qRT-PCR |
cell lines (MCF10A, RPMI 1640, DMEM H21 etc.) |
up-regulated |
expression |
Down-regulation of H19 significantly decreases breast and lung cancer cell clonogenicity and anchorage-independent growth. In addition, c-Myc and H19 expression shows strong association in primary breast and lung carcinomas. |
16707459 |
| colon cancer |
|
N/A |
N/A |
N/A |
expression |
DT-A was preferentially expressed in liver metastases after being transfected with H19 or IGF2-P3 promoter-driven DT-A expression plasmids, causing a very significant inhibition of tumor growth as a result of its cytotoxic effect. |
15521051 |
| cancer |
|
N/A |
N/A |
N/A |
expression |
H19 expression was found in the hepatic metastases of 64 of 80 patients. High expression (higher staining grades) of H19 in the metastases was found in 43 of 80 patients. However, H19 expression status in the hepatic metastases did not correlate with either the length of time to development of metastasis or overall survival. |
16189152 |
| Wilms' tumor |
|
Southern blot, Northern blot |
Wilms' tumor tissue |
differential expression |
epigenetics |
Gain of methylation at the H19 DMR is an early event in Wilms' tumorigenesis that is independent of chromosomal losses. |
16179496 |
| germ cell tumor |
|
qRT-PCR |
germ cell tumor tissue |
differential expression |
epigenetics |
IGF2/H19 methylation status in GCTs might reflect preservation of the physiologic imprinting erasure in PGCs rather than a loss of imprinting in a sense that is accepted for somatic tumors. |
16001432 |
| chronic myeloproliferative disorders |
|
N/A |
N/A |
N/A |
expression |
Reduced expression of H19 in bone marrow cells from chronic myeloproliferative disorders. |
12682647 |
| breast cancer |
|
qRT-PCR, Northern blot |
breast cancer tissue |
differential expression |
expression |
H19 RNA and insulin-like growth factor II mRNA were up-regulated significantly in non-neoplastic WAP-CRD-BP mammary tissue. |
14729626 |
| hyperhomocysteinemia |
|
N/A |
N/A |
N/A |
epigenetics |
The effect of hyperhomocysteinemia on H19 DMD methylation was tissue-specific. hyperhomocysteinemia produces tissue-specific changes in H19 DMD methylation and increased vascular expression of H19 in adult mice. |
15899898 |
| gestational trophoblastic diseases |
|
N/A |
N/A |
N/A |
expression |
LOI, deregulation of IGF2 promoters, and the altered expression levels of IGF2 and H19 genes might be associated with the progression of GTD. |
12648595 |
| bladder cancer |
|
PCR-RFLP |
blood |
differential expression |
mutation |
A significantly decreased risk of bladder cancer was found for the rs2839698 TC genotype but not for CC homozygotes.The rs2839698 TC genotype was especially associated with a reduced risk of developing non-muscle-invasive disease. Borderline significantly |
18262338 |
| melanoma |
|
N/A |
N/A |
N/A |
expression |
The study of 4 sensitive and 2 resistant cell lines allowed the identification of 4 genes (RCC1, IFI16, hox2 and h19) preferentially transcribed in sensitive ((IFN-alpha therapy) cells and 2 (SHB and PKC-zeta) preferentially expressed in resistant cells. |
11437411 |
| meningioma |
|
qRT-PCR |
meningioma tissue |
differential expression |
N/A |
In total, 24 meningiomas of WHO grade I, II and III were analysed. 15 meningiomas (63%) were informative for the ApaI polymorphism in the IGF2 gene. Monoallelic expression (MAE) for IGF2 was found in 11 out of 15 tumours (73%) which is in contrast to the lack of imprinting status of IGF2 in leptomeninges. Ten cases (42%) were heterozygous for the H19 gene and biallelic expression was found in 3 out of 10 meningiomas (30%). These results indicate that modulation of the imprinting status of IGF2 and H19 may play an important role for the development of meningiomas. |
10738131 |
| Silver-Russell syndrome |
|
N/A |
N/A |
N/A |
mutation |
Epigenetic mutations of the imprinted IGF2-H19 domain in Silver-Russell syndrome |
19066168 |
| Marek's disease |
|
N/A |
N/A |
N/A |
mutation |
The mutant CVI/rpp38 was not only reactive with MAb H19 in IFA but also in immunoprecipitation. |
10696440 |
| Beckwith-Wiedemann syndrome |
|
N/A |
N/A |
N/A |
mutation |
Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome. |
15314640 |
| hepatocellular carcinoma |
|
microarray, qRT-PCR, knockdown, ISH |
cell lines (T24P, HepG2, Hep3B etc.) |
up-regulated |
N/A |
The H19 non-coding RNA is essential for human tumor growth. |
17786216 |
| bladder cancer |
|
microarray, qRT-PCR, knockdown, ISH |
cell lines (T24P etc.) |
up-regulated |
N/A |
The H19 non-coding RNA is essential for human tumor growth. |
17786216 |
| medulloblastoma |
|
qRT-PCR |
fetal cerebella tissue, cell lines (MEB-MED, D283 etc.) |
differential expression |
expression |
Loss of imprinting of H19 occurred in 0 out of 4 informative fetal cerebella, 0 out of 1 informative adult cerebellum, 4 out of 8 informative medulloblastomas, and 1 out of 4 informative cell lines. The biallelic expression of H19 was only partial in two medulloblastomas, however, with one allele being significantly weaker than the other. |
8957451 |
| breast cancer |
|
qRT-PCR, ISH |
MDA-MB-231 cell line |
up-regulated |
expression |
Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. |
12419837 |
| cervical cancer |
|
N/A |
N/A |
N/A |
mutation |
High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. |
8570220 |
| growth restriction |
|
N/A |
N/A |
N/A |
epigenetics |
A loss of methylation at H19. |
20104244 |
| infertility |
|
N/A |
N/A |
N/A |
expression |
H19 expression was lower in the infertility group as compared to the control group. |
20042264 |
| melanoma |
|
N/A |
N/A |
N/A |
expression |
H19 RNA downregulation stimulated melanogenesis in melasma. |
19968822 |
| colon cancer |
|
qRT-PCR, Northern blot, ISH |
CRC tissue |
up-regulated |
locus |
Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. |
19926638 |
| trophoblastic tumor |
|
ISH |
placenta tissue |
up-regulated |
expression |
Prominent expression of H19 was found in placental site trophoblastic tumor and gestational choriocarcinoma. |
8188082 |
| gestational choriocarcinoma |
|
ISH |
placenta tissue |
up-regulated |
expression |
Prominent expression of H19 was found in placental site trophoblastic tumor and gestational choriocarcinoma. |
8188082 |
| Beckwith-Wiedemann syndrome |
|
N/A |
N/A |
N/A |
epigenetics |
Allelic methylation of H19 and IGF2 in the Beckwith-Wiedemann syndrome. |
7987305 |
| ovarian cancer |
|
qRT-PCR, knockdown |
cell lines (PC3, C2C12 etc.) |
up-regulated |
expression |
H19 RNA was detected in 90% of patients with OCAF (Ovarian cancer ascites fluid ) as determined by ISH. Intratumoral injection of DTA-H19 into ectopically developed tumors caused 40% inhibition of tumor growth. |
19656414 |
| Beckwith-Wiedemann syndrome |
|
N/A |
N/A |
N/A |
epigenetics |
Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. |
11813134 |
| breast cancer |
|
qRT-PCR, knockdown |
breast cancer tissue, cell lines (MCF7, T47D, BT20 etc.) |
up-regulated |
expression |
the transcript is stabilized in breast cancer cells and overexpressed in human breast tumors.91H expression is upregulated in breast cancer. |
18794369 |
| pre-eclampsia |
|
N/A |
N/A |
N/A |
mutation |
LOI of H19 can be identified in pre-eclamptic placentas and is associated with maternal blood pressures, which implies the involvement of H19 gene LOI in the pathogenesis of pre-eclampsia and its potential relationship with the severity of the disease. |
19570415 |
| Beckwith-Wiedemann syndrome |
|
N/A |
N/A |
N/A |
locus |
The H19 locus acts in vivo as a tumor suppressor. |
18719115 |
| glioblastoma |
|
N/A |
N/A |
N/A |
expression |
Another study performed in CD133+ and CD133- glioblastoma derived primary cell lines revealed levels of H19 expression that were relatively high and low, respectively. |
20380817 |
| medulloblastoma |
|
N/A |
N/A |
N/A |
epigenetics |
A study of medulloblastomas and medulloblastoma cell lines showed partial loss of imprinting (LOI) and biallelic expression of H19. |
20380817 |
| meningioma |
|
N/A |
N/A |
N/A |
epigenetics |
An examination of meningiomas (World Health Organization grades I-III) demonstrated more robustly that the imprinting status of H19 is perturbed with LOI in a significant number of these tumors. |
20380817 |
| melanoma |
|
N/A |
N/A |
N/A |
mutation |
Although the IGF2 and H19 genotypes/haplotypes were not significantly associated with melanoma, two of the most severe cases (very early onset or multiple melanomas) showed to be heterozygous for both genes. |
20483645 |
| Wiedemann-Beckwith syndrome |
|
N/A |
N/A |
N/A |
epigenetics |
Genetic analyses of the patient's blood showed hypermethylation at the H19 locus on chromosome 11p. |
21058226 |
| Silver-Russell syndrome |
|
N/A |
N/A |
N/A |
epigenetics |
The major finding (~44%) is a hypomethylation of the imprinting control region 1 (ICR1) in 11p15.5 affecting the expression of H19 and IGF2. 4-10% of the patients carry a maternal UPD of chromosome 7 (UPD(7)mat). |
21150838 |
| bladder cancer |
|
qRT-PCR, ISH |
cell lines (T24P, HT-1376 etc.) |
up-regulated |
N/A |
Bladder tumors may be successfully treated by intravesical instillation of the double promoter vector H19-DTA-P4-DTA. |
21162716 |
| liver cancer |
|
N/A |
N/A |
N/A |
epigenetics |
H19 ICR showed loss-of-imprinting in two steps and allelic histone marker signature during tumorigenesis showed similarity with ES cells. |
21163252 |
| Mullerian aplasia |
|
N/A |
N/A |
N/A |
epigenetics |
Methylation of H19 and its imprinted control region (H19 ICR1) in Mullerian aplasia. |
21458801 |
| breast cancer |
|
qRT-PCR |
breast cancer tissue |
differential expression |
mutation |
rs2107425 (C>T) near H19 was significantly associated with shorter metastasis-free survival in uni- and multi-variate analysis , with the more aggressive minor allele displaying a recessive trait. |
21748294 |
| colon cancer |
|
N/A |
N/A |
N/A |
N/A |
Regional therapy with DTA-H19 vector suppresses growth of colon adenocarcinoma metastases in the rat liver. |
21874233 |
| pheochromocytoma |
|
N/A |
N/A |
N/A |
mutation |
Tumor DNA from the index patient revealed loss of heterozygosity (LOH) at 11q23, causing loss of the wild-type paternal SDHD allele and LOH affecting maternal 11p15, including H19. |
21937622 |
| atherosclerosis |
|
N/A |
N/A |
N/A |
epigenetics |
The most pronounced differences of atherosclerotic plaques in DNA methylation levels were registered for a site which is located in CpG-island of imprinted gene H19. |
21954592 |
| breast cancer |
|
N/A |
N/A |
N/A |
mutation |
Different SNPs in LSP1 and H19 and in minor genes probably were associated with BC risk. |
21996731 |
| adrenocortical carcinomas |
|
N/A |
N/A |
N/A |
epigenetics |
This disease has been associated with structural abnormalities at the 11p15 locus, which harbors the IGF2 gene as well as the genes coding for insulin, H19, and p57kip2. |
22019903 |
| neural tube defects |
|
N/A |
N/A |
N/A |
epigenetics |
The methylation levels of H19 DMR1 in the NTD and control groups are 73.3%卤15.9 and 58.3%卤11.2, respectively. Hyper-methylation of the H19 DMR1 may be correlated with the occurrence of NTDs. |
22234160 |
| obesity |
|
N/A |
N/A |
N/A |
epigenetics |
Insulin-like Growth Factor 2/H19 Methylation at Birth and Risk of Overweight and Obesity in Children. |
22341586 |
| colorectal cancer |
|
qRT-PCR, RFLP-PCR |
CRC tissue |
up-regulated |
N/A |
The results of the present study suggest that LOI of IGF2 is important in the carcinogenesis of CRC. Hypomethylation of the sixth CTCF-binding site in the DMR of IGF2/H19 is linked to LOI and the common IGF2-H19 enhancer competition model for IGF2 imprinting does not apply to human CRC. |
22427002 |
| Wilms' tumor |
|
N/A |
N/A |
N/A |
epigenetics |
37% of patients with Wilms' tumor were H19 epimutations. |
22470196 |
| gastric cancer |
|
qRT-PCR, Luciferase reporter assays,knockdown, RIP |
gastric cancer tissue, cell lines (AGS, MKN45, MGC803, SGC7901, GES-1 etc.) |
up-regulated |
N/A |
We demonstrated that H19 levels were markedly increased in gastric cancer cells and gastric cancer tissues compared with normal controls. Moreover, ectopic expression of H19 increased cell proliferation, whereas H19 siRNA treatment contributed to cell apoptosis in AGS cell line. We further verified that H19 was associated with p53, and that this association resulted in partial p53 inactivation. |
22776265 |
| bladder cancer |
|
N/A |
N/A |
N/A |
expression |
Control of imprinting. Containing miRNA miR-675. |
22996375 |
| breast cancer |
|
N/A |
N/A |
N/A |
expression |
Control of imprinting. Containing miRNA miR-675. |
22996375 |
| choriocarcinoma |
|
N/A |
N/A |
N/A |
expression |
Control of imprinting. Containing miRNA miR-675. |
22996375 |
| colon cancer |
|
N/A |
N/A |
N/A |
expression |
Control of imprinting. Containing miRNA miR-675. |
22996375 |
| esophageal squamous cell carcinoma |
|
N/A |
N/A |
N/A |
expression |
Control of imprinting. Containing miRNA miR-675. |
22996375 |
| liver cancer |
|
N/A |
N/A |
N/A |
expression |
Control of imprinting. Containing miRNA miR-675. |
22996375 |
| lung cancer |
|
N/A |
N/A |
N/A |
expression |
Control of imprinting. Containing miRNA miR-675. |
22996375 |
| hepatocellular carcinoma |
|
qRT-PCR, Western bolt, Northern bolt, knockdown, RIP |
HCC tissue, cell lines(SMMC7721, HCCLM3) |
down-regulated |
expression |
Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. |
23222811 |
| bladder cancer |
|
qRT-PCR, Luciferase reporter assay, knockdown, RIP |
bladder cancer tissue, cell lines (RT4, RT112, DSH1, 253J, TCCSUP etc.) |
up-regulated |
expression |
Upregulated H19 contributes to bladder cancer cell proliferation by regulating ID2 expression. |
23354591 |
| bladder cancer |
|
qRT-PCR, western blot |
bladder cancer tissue, cell lines (RT4, RT112, DSH1, 253J, TCCSUP etc.) |
up-regulated |
expression |
Upregulated H19 contributes to bladder cancer cell proliferation by regulating ID2 expression. |
23399020 |
| tumor |
|
N/A |
N/A |
N/A |
epigenetics |
In recent years, we have extensively investigated the expression of the H19 gene in a number of human cancers and explored the role of H19 RNA in tumor development. |
23429271 |
| tumor |
|
N/A |
N/A |
N/A |
expression |
H19, a lncRNA with oncogenic properties, is upregulated in a wide range of tumours. |
23660942 |
| glioma |
|
N/A |
N/A |
N/A |
expression |
Epigenetic deregulation of lncRNAs genes is associated with disease |
23791884 |
| medulloblastoma |
|
N/A |
N/A |
N/A |
expression |
Epigenetic deregulation of lncRNAs genes is associated with disease |
23791884 |
| meningioma |
|
N/A |
N/A |
N/A |
expression |
Epigenetic deregulation of lncRNAs genes is associated with disease |
23791884 |
| neuroblastoma |
|
N/A |
N/A |
N/A |
expression |
Epigenetic deregulation of lncRNAs genes is associated with disease |
23791884 |
| pituitary adenoma |
|
N/A |
N/A |
N/A |
expression |
Epigenetic deregulation of lncRNAs genes is associated with disease |
23791884 |
| Prader-Willi syndrome |
|
N/A |
N/A |
N/A |
expression |
Epigenetic deregulation of lncRNAs genes is associated with disease |
23791884 |
| gastric cancer |
|
qRT-PCR |
gastric cancer tissue, cell lines (HGC27) |
up-regulated |
N/A |
Plasma H19 levels were significantly higher in patients than in healthy controls (p=0.029). Circulating lncRNAs can be detectable in plasma, and the detection of circulating lncRNAs may provide new complementary tumor markers for gastric cancer. |
23898077 |
| bladder cancer |
|
N/A |
N/A |
N/A |
expression |
Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs |
24006935 |
| gastric cancer |
|
microarray, qRT-PCR |
gastric cancer tissue, cell lines (GES-1, AGS, MGC-803, SGC-7901) |
up-regulated |
N/A |
As shown in Figure 2D, comparing with respective normal cell line, H19 was found highly expressed in stomach cancer cell lines (AGS, MGC-803 and SGC-7901) and hepatocellular carcinoma cell lines (SMMC-7721 and HepG2), while lowly expressed in lung cancer cell line (A549) and prostate cancer cell lines (Du-145 and PC-3). |
24063685 |
| hepatocellular carcinoma |
|
microarray, qRT-PCR |
cell lines (SMMC-7721, HepG2) |
up-regulated |
N/A |
Comparing with respective normal cell line, H19 was found highly expressed in stomach cancer cell lines (AGS, MGC-803 and SGC-7901) and hepatocellular carcinoma cell lines (SMMC-7721 and HepG2), while lowly expressed in lung cancer cell line (A549) and prostate cancer cell lines (Du-145 and PC-3). |
24063685 |
| lung cancer |
|
microarray, qRT-PCR |
cell lines (A549) |
down-regulated |
N/A |
Comparing with respective normal cell line, H19 was found highly expressed in stomach cancer cell lines (AGS, MGC-803 and SGC-7901) and hepatocellular carcinoma cell lines (SMMC-7721 and HepG2), while lowly expressed in lung cancer cell line (A549) and prostate cancer cell lines (Du-145 and PC-3). |
24063685 |
| prostate cancer |
|
microarray, qRT-PCR |
cell lines ((Du-145, PC-3) |
down-regulated |
N/A |
Comparing with respective normal cell line, H19 was found highly expressed in stomach cancer cell lines (AGS, MGC-803 and SGC-7901) and hepatocellular carcinoma cell lines (SMMC-7721 and HepG2), while lowly expressed in lung cancer cell line (A549) and prostate cancer cell lines (Du-145 and PC-3). |
24063685 |
| hepatocellular carcinoma |
|
N/A |
N/A |
N/A |
expression |
Dysregulation and functional roles of lncRNAs in HCC |
24183851 |
| skin cancer |
|
qRT-PCR, microarray |
cultured mouse keratinocytes after deleting the vitamin D receptor (VDR) (∼90%) vs. control cells
|
up-regulated |
expression |
Several well-known oncogenes, including H19, HOTTIP and Nespas, are significantly increased (6.3-1.8-fold), whereas tumor suppressors (Kcnq1ot1, lincRNA-p21) are decreased (up to 50-70%) in VDR deleted keratinocytes.
|
24342142 |
| bladder cancer |
|
N/A |
N/A |
N/A |
expression |
Prognostic marker low-risk marker Oncogene targeted therapy agent |
24373479 |
| kidney cancer |
|
N/A |
N/A |
N/A |
expression |
Tumour suppressor; tumour suppressor host |
24373479 |
| prostate cancer |
|
N/A |
N/A |
N/A |
expression |
Putative susceptibility and diagnostic marker |
24373479 |
| ovarian cancer |
|
microarray, qRT-PCR |
ovarian cancer tissue, cell lines (SKOV3, SKOV3.ip1 etc.) |
down-regulated |
N/A |
The qPCR results of seven lncRNAs (MALAT1, H19, UCA1, CCAT1, LOC645249, LOC100128881, and LOC100292680) were consistent with the deregulation found by microarray analysis, reflecting the reliability of the microarray data to some extent. |
24379988 |
| gastric cancer |
|
qRT-PCR, western blot, knockdown |
gastric cancer tissue, cell lines (AGS, MGC803 etc.) |
up-regulated |
N/A |
The expression levels of H19 and miR-675 in five gastric cancer cell lines were correlated with each other (r = 0.9910, P = 0.0315, data not shown). We next assessed the correlation of miR-675 and H19 expression in 24 human gastric cancer tissues. The expression of H19 and miR-675 in gastric cancer tissues was correlated with each other (r = 0.8214, P < 0.01). |
24388988 |
| gastric cardia adenocarcinoma |
|
microarray, qRT-PCR |
gastric cancer tissue |
up-regulated |
N/A |
H19 expression level was 4.97 to 13.58-fold higher in GCa samples than the mean level in paired non-cancerous tissues. Moreover, the expression levels of H19 were increased significantly in the tumors of patients with advanced clinical stage (p < 0.001) and larger tumor size ( p < 0.001). |
24414129 |
| glioma |
|
microarray, qRT-PCR |
glioma tissue, cell lines (U87, U251 etc.) |
up-regulated |
expression |
Long non-coding RNA H19 promotes glioma cell invasion by deriving miR-675. |
24466011 |
| bladder cancer |
|
N/A |
N/A |
N/A |
expression |
Control of imprinting breast, cervix, oesophagus prostate, endometrial, colon |
24499465 |
| liver cancer |
|
N/A |
N/A |
N/A |
expression |
Control of imprinting breast, cervix, oesophagus prostate, endometrial, colon |
24499465 |
| lung cancer |
|
N/A |
N/A |
N/A |
expression |
Control of imprinting breast, cervix, oesophagus prostate, endometrial, colon |
24499465 |
| gastric cancer |
|
qRT-PCR, knockdown |
gastric cancer tissue, cell lines MGC-803, SGC-7901, GES-1) |
up-regulated |
expression |
c-Myc-induced, long, noncoding H19 affects cell proliferation and predicts a poor prognosis in patients with gastric cancer. |
24671855 |
| chronic myeloid leukemia |
|
qRT-PCR, western blot |
cell lines (K562) |
up-regulated |
N/A |
We observed that H19 was highly expressed in Bcr-Abl-expressing primary CML cells derived from 4 patients, and imatinib treatment greatly decreased the expression of H19 in these cells but not in normal control cells. Loss of either Bcr-Abl expression or Abl kinase activity caused decrease of c-Myc levels with simultaneously reduced levels of H19. Furthermore, we demonstrated that depletion of c-Myc alone in K562 cells significantly decreased the level of H19, suggesting that H19 is expressed in a c-Myc dependent manner in K562 leukemic cells. |
24685695 |
| tumor |
|
N/A |
N/A |
N/A |
expression |
Oncofetal H19 RNA promotes tumor metastasis. |
24703882 |
| esophageal squamous cell carcinoma |
|
qRt-PCR, knockdown |
ESCC tissue, cell lines (TE-1 , Eca-109) |
down-regulated |
expression |
Long non-coding RNA 91H contributes to the occurrence and progression of esophageal squamous cell carcinoma by inhibiting IGF2 expression. |
24706416 |
| hepatocellular carcinoma |
|
N/A |
N/A |
N/A |
expression |
Overexpression of H19 was found in hepatocellular carcinoma.? |
24757675 |
| hepatocellular carcinoma |
|
qRT-PCR, western blot, knockdown |
cell lines (HepG2) |
up-regulated |
N/A |
We found that AFB1 could up-regulate the expression of H19 and promote cell growth and invasion by hepatocellular carcinoma HepG2 cells. AFB1 induced the expression of E2F1 and its knock-down could down-regulate H19 expression and suppress cell growth and invasion in hepatocellular carcinoma HepG2 cells. E2F1 over-expression could up-regulate H19 expression and promote cell growth and invasion, with binding to the H19 promoter being demonstrated by chromatin immunoprecipitation assays. |
24761865 |
| gastric cancer |
|
qRT-PCR, western blot, Luciferase reporter assays, knockdown |
gastric cancer tissue, cell lines (SGC7901, MKN45, MKN-28 etc.) |
up-regulated |
expression |
Overexpression of?lncRNA?H19 enhances carcinogenesis and metastasis of gastric cancer. |
24810858 |
| gastric cancer |
|
N/A |
N/A |
N/A |
expression |
Using real-time RT-PCR, flow cytometry, RNA immunoprecipitation and other methods, Yang et al confirmed that H19 expression in gastric cancer accelerated cell proliferation. |
24833871 |
| pancreatic ductal adenocarcinoma |
|
qRT-PCR, western blot, knockdown |
pancreatic cancer tissue, cell lines (PANC-1, SW1990, AsPC-1, BxPC-3, CFPAC-1 etc.) |
up-regulated |
N/A |
The levels of H19 was overexpressed in PDAC and was upregulated remarkably in primary tumors which subsequently metastasized, compared to those did not metastasis. H19 promoted PDAC cell invasion and migration. An important role of H19 in regulating metastasis of PDAC and provides some clues for elucidating the lncRNAmiRNA functional network in cancer. |
24920070 |
| hepatocellular carcinoma |
|
qRT-PCR, western blot, knockdown |
cell lines (Huh-7, MHCC-97H, HepG2 etc.) |
up-regulated |
N/A |
The expression levels of LncRNAH19 and miR-675 were higher in MHCC-97H cells than in L02, Huh-7 and HepG2 cells. Transwell migration assay revealed that the miR-675 inhibitor and LncRNAH19siRNA could significantly increase the migration of HCC cells as compared with the control group. Transwell invasion assay demonstrated that the miR-675 inhibitor and LncRNAH19siRNA could significantly increase the invasion of HCC cells as compared with the control group. Inhibition of LncRNAH19 and miR-675 expression can promote migration and invasion of HCC cells via AKT/GSK-3β/Cdc25A signaling pathway. |
24939300 |
| prostate cancer |
|
qRT-PCR, western blot |
cell lines (P69, M12) |
down-regulated |
N/A |
In this study, we found that long non-coding RNA H19 (H19) and H19-derived microRNA-675 (miR-675) were significantly downregulated in the metastatic prostate cancer cell line M12 compared with the non-metastatic prostate epithelial cell line P69. Upregulation of H19 in P69 and PC3 cells significantly increased the level of miR-675 and repressed cell migration; however, ectopic expression of H19 in M12 cells could not increase the level of miR-675 and therefore had no effect on cell migration. |
24988946 |
| colorectal cancer |
|
qRT-PCR, knockdown |
CRC tissue, cell lines ( HCT8, HT29, HCT116, SW620 etc.) |
up-regulated |
expression |
91H was significantly overexpressed in cancerous tissue and CRC cell lines compared with adjacent normal tissue and a normal human intestinal epithelial cell line. Moreover, 91H overexpression was closely associated with distant metastasis and poor prognosis in patients with CRC, except for CNV of 91H. Multivariate analysis indicated that 91H expression was an independent prognostic indicator, as well as distant metastasis. 91H played an important role in the molecular etiology of CRC and might be regarded as a novel prognosis indicator in patients with CRC. |
25058480 |
| coronary artery disease |
|
N/A |
N/A |
N/A |
N/A |
Re-expression of H19 has been observed in patients with atherosclerosis. Common polymorphisms of H19 are associated with the risk and severity of CAD in a Chinese population. |
25772106 |
| breast cancer |
|
qRT-PCR, western blot, knockdown |
breast cancer tissue, cell lines (MCF-7, MDA-MB-231) |
up-regulated |
N/A |
H19 lncRNA mediates 17beta-estradiol-induced cell proliferation in MCF-7 breast cancer cells; H19 lncRNA was much higher in estrogen receptor (ER)-positive MCF-7 breast cancer cells than in ER-negative MDA-MB-231 cells |
25846769 |
| clear cell renal cell carcinoma |
|
qRT-PCR, knockdown |
clear cell renal carcinoma (ccRCC) tissues and renal cancer cell lines |
up-regulated |
expression |
lncRNA H19 might be considered as a potential prognostic indicator and a target for gene therapy of ccRCC. |
25866221 |
| gastric cancer |
|
|
gastric cancer samples |
up-regulated |
mutation |
We genotyped four lncRNA H19 single nucleotide polymorphisms (SNPs)(rs217727 C > T, rs2839698 C > T, rs3741216 A > T, rs3741219 T > C) in 500 GC patients and 500 healthy controls. These findings suggest that lncRNA H19 SNPs may contribute to susceptibility to GC. |
25944697 |
| gastric cancer |
|
qRT-PCR |
gastric cancer tissue, cell lines(AGS, MKN45, 7901 etc.) |
up-regulated |
expression |
After validating in 20 pairs of tissues and plasma in training set, H19 was selected for further analysis in another 70 patients and 70 controls. Plasma level of H19 was significantly higher in GC patients compared with normal controls. |
26096073 |
| esophageal cancer |
|
qRT-PCR, western blot, knockdown |
esophageal cancer tissue, cell lines (TE-1, TE-10, Eca-1, Eca-109, KYSE1170) |
up-regulated |
expression |
The expression of H19 was significantly increased and associated with tumor depth and metastasis in 133 EC samples. In addition, it was identified that an upregulation of H19 induced epithelial-to-mesenchymal transition. In conclusion, H19 has a significant role in the development of EC and may serve as a potential prognostic marker and therapeutic target for EC. |
26171017 |
| gastric cancer |
|
microarray, qRT-PCR |
gastric cancer tissue, cell lines (HCG-27, SGC-7901) |
up-regulated |
expression |
H19 and HOTAIR displayed significantly higher levels and the up-regulation of HOTAIR was associated with lymphatic metastasis and poor differentiation. |
26237576 |
| liver cancer |
|
qRT-PCR |
hepatocellular carcinoma tissue |
up-regulated |
expression |
LncRNA profiling revealed that CD90+ cells were enriched in lncRNA H19, and released this through exosomes.Experiments of gain and loss of function of H19 showed that this LncRNA plays an important role in the exosome-mediated phenotype of endothelial cells. Moreover, we suggest the lncRNA H19 as a putative therapeutic target in hepatocellular carcinoma. |
26272696 |
| glioblastoma |
|
qRT-PCR, |
glioblastoma tissue, cell lines (U87, U373) |
up-regulated |
expression |
H19 is significantly overexpressed in glioblastoma tissues, and the level of expression was associated with patient survival. In the subsequent investigations, the authors found that overexpression of H19 promotes glioblastoma cell invasion and angiogenesis in vitro. Interestingly, H19 was also significantly overexpressed in CD133+ glioblastoma cells, and overexpression of H19 was associated with increased neurosphere formation of glioblastoma cells. |
26274999 |
| breast cancer |
|
CISH |
breast cancer tissue |
up-regulated |
expression |
HOTAIR, H19 and KCNQ1OT1 had significantly higher expression levels in IBC than NA, and HOTAIR and H19 were both expressed more strongly in IBC than in DCIS tissues. |
26323944 |
| ovarian cancer |
|
qRT-PCR, western blot, knockdown |
ovarian cancer tissues and adjacent normal tissues, cell lines (SKOV3, OV90, TOV112D, ES2) |
up-regulated |
expression |
Our results demonstrated that that H19 silencing inhibited OV90 and SKOV3 OC cell proliferation in vitro. Further investigation into the mechanisms responsible for the growth inhibitory effects by H19 silencing revealed that its knockdown resulted in the induction of cell cycle arrest and apoptosis through certain cell cycle-related and apoptosis-related proteins |
26617715 |
| gastric cancer |
|
qRT-PCR |
gastric cancer (GC) tissues |
up-regulated |
expression |
H19 might serve as a promising biomarker for early detection and prognosis prediction of GC. |
26774144 |
| laryngeal squamous cell carcinoma |
|
knockdown |
LSCC patients |
up-regulated |
N/A |
The inhibition of LSCC progression induced by H19 knockdown required the activity |
26872375 |
| gastric cancer |
|
knockout |
gastric cancer AGS cells |
down-regulated |
N/A |
H19 or miR-675 enhanced RUNX1 expression |
26931432 |
| glioblastoma multiforme |
|
N/A |
GBM cell lines |
up-regulated |
N/A |
H19 in contributing to GBM malignancy |
26983719 |
| colorectal cancer |
|
a case-control study |
N/A |
N/A |
N/A |
N/A |
27027436 |
| gallbladder cancer |
|
|
gallbladder cancer tissues and adjacent normal tissues |
up-regulated |
N/A |
The overexpression of H19 in GBC cells enhanced tumor invasion and promoted EMT |
27073719 |
| cardiac hypertrophy |
|
N/A |
normal and diseased hearts |
up-regulated |
N/A |
overexpression of H19 reduced cell size both at baseline and in response to PE; knockdown of
H19 induced cardiomyocyte hypertroph |
27084844 |
| heart failure |
|
N/A |
normal and diseased hearts |
up-regulated |
N/A |
overexpression of H19 reduced cell size both at baseline and in response to PE; knockdown of
H19 induced cardiomyocyte hypertroph |
27084844 |
| gastric cancer |
|
qRT-PCR |
GC cells |
up-regulated |
expression |
Up-regulation of H19 is closely associated with gastric cancer displaying progressive up-regulation in advanced stages of the disease implementing its role as a potential non-invasive diagnostic biomarker in gastric |
27184562 |
| esophageal squamous cell carcinoma |
|
qRT-PCR, knockdown, western blot, |
esophageal squamous cell carcinoma cells and tissues |
up-regulated |
expression |
Long noncoding RNA H19 is up-regulated in esophageal squamous cell carcinoma and promotes cell proliferation and metastasis. |
27247022 |
| cardiac fibrosis |
|
qRT-PCR, knockdown, overexpression, western blot, immunohistochemistry assay, |
cardiac fibrosis tissue |
up-regulated |
expression |
Down-regulation of DUSP5 has been shown to increase cell proliferation. DUSP5 expression is regulated through epigenetic events involving LncRNA H19 human choriocarcinoma cell line. |
27318893 |
| endometrial cancer |
|
qRT-PCR, Western-blot |
the Ishikawa cell control group, the 5 mg/L and the 10 mg/L mifepristone treatment groups |
up-regulated |
expression |
Mifepristone inhibits the migration of endometrial carcinoma cells partially through methylation-induced of transcriptional inhibition of H19, which results in the down-regulation of HMGA2 and vimentin and upregulation of E-cadherin. |
27346397 |
| breast cancer |
|
qRT-PCR |
BC tissues and plasma compared with healthy controls |
up-regulated |
expression |
The expression of H19 was significantly increased in BC tissues and plasma compared with healthy controls (P< 0.05), and plasma H19 levels were significantly correlated with estrogen receptor (ER) (P= 0.008), progesterone receptor (PR) (P= 0.025), c-erbB-2 (P= 0.043) and lymph node metastasis (P= 0.006). The area under the ROC curve (AUC) of plasma H19 was 0.81(sensitivity, 56.7%; specificity, 86.7%; P< 0.0001), which was higher than the values of carcinoembryonic antigen (CEA) and carbohydrate antigen 153 (CA153). Furthermore, plasma H19 levels were significantly decreased in postoperative samples than preoperative samples (P= 0.0006). |
27540977 |
| pancreatic ductal adenocarcinoma |
|
qRT-PCR, Knockdown, overexpression, western blot, immunohistochemical analysis |
pancreatic cancer cells |
up-regulated |
expression |
Knockdown of H19 in T3M4 and PANC-1 cells with high H19 endogenous level suppressed cell viability, proliferation and tumor growth, while H19 overexpression in COLO357 and CAPAN-1 with low H19 endogenous level enhanced cell viability, proliferation and tumor growth. |
27573434 |
| cervical cancer |
|
overexpression, knockdown, |
cervical cancer cell lines |
up-regulated |
expression |
H19 promotes both anchorage-specific and -independent growth of cervical cancer cell lines and may serve as a potential target for cancer diagnosis and therapy. |
27633578 |
| ulcerative colitis |
|
qRT-PCR |
ulcerative colitis (UC) tissues |
down-regulated |
expression |
H19 overexpression on intestinal epithelial barrier function and suggests a potential role of H19 in the development of UC. |
27661667 |
| calcific aortic valve disease |
|
RNA-seq, knockdown, overexpression |
valve interstitial cells |
up-regulated |
epigenetics |
These findings indicate that a dysregulation of DNA methylation in the promoter of H19 during calcific aortic valve disease is associated with a higher expression of this lncRNA, which promotes an osteogenic program by interfering with the expression of NOTCH1. |
27789555 |
| non-small cell lung cancer |
cisplatin |
knockdown |
human lung adenocarcinoma cells |
up-regulated |
expression |
H19-mediated regulation of cisplatin resistance in human lung adenocarcinoma cells is demonstrated for the first time |
27911863 |
| colorectal cancer |
methotrexate(MTX) |
Knockdown, overexpression |
MTX-resistant colorectal cell line HT-29 |
up-regulated |
expression |
The Wnt/β-catenin signaling was activated in HT-29-R cells, and H19 knockdown suppressed this signaling in the parental cells. |
27919747 |
| glioma |
|
qRT-PCR, knockdown |
35 specimens of glioma vs control tissue, and two glioma cell lines U251 and U87 vs Normal Human Astrocyte (NHA) cells |
up-regulated |
expression |
LncRNA H19 is overexpressed in glioma tissue, and is positively associated with the tumor grade and negatively associated with patient survival. In cell culture studies, lncRNA H19 promotes glioma cell proliferation. |
27981546 |
| head and neck squamous cell carcinoma |
|
Knockdown |
65 primary tumor samples and two HNSCC cell lines |
up-regulated |
expression |
These results suggest that the strong correlation of H19 overexpression together with higher miR-675 and lymph node metastases could be useful predictive markers, indicating a potentially therapeutic strategy for HNSCC patients. |
27994496 |
| breast cancer |
|
knockdown |
breast cancer stem cells (BCSCs) |
up-regulated |
expression |
LncRNA H19, miRNA let-7 and transcriptional factor LIN28 form a double-negative feedback loop, which has a critical role in the maintenance of BCSCs. |
28102845 |
| gastric cancer |
curcumin |
qRT-PCR, western blotting |
gastric cancer cell line SGC-7901 |
down-regulated |
expression |
Curcumin inhibits the proliferation of gastric cancer cells by downregulating the c-Myc/H19 pathway. |
28105222 |
| endometrial cancer |
|
qRT-PCR, knockdown |
endometrial cancer cells |
down-regulated |
expression |
H19 contributed to the aggressiveness of endometrial cancer by modulating EMT process |
28123568 |
| atherosclerosis |
|
qRT-PCR, western blot |
Blood sample were collected from 42 patients with atherosclerosis and 37 healthy volunteers |
up-regulated |
expression |
LncRNA H19 promotes atherosclerosis by regulating MAPK and NF-kB signaling pathway. |
28165553 |
| cerebral ischemia/reperfusion injury |
|
qRT-PCR, mmunofluorescence,western blot |
SH-SY5Y cells , rat cells |
up-regulated |
expression |
The expression of lncRNA H19 was upregulated by cerebral I/R in rats, as well as by OGD/R in vitro in the cells. |
28203482 |
| azoospermia |
|
|
spermatogenic cells |
|
epigenetics |
H19 imprinting errors in primary spermatocytes from one MAi patient and MEST imprinting errors in one MAi and two MAc patients. Additionally, H19 imprinting errors were observed in elongated spermatids/spermatozoa from one MAi patient. Nevertheless, no statistical differences were found for H19 and MEST global methylation levels (percentage of methylated and unmethylated CpGs, respectively) between patients with complete and incomplete MA and also between MA groups and a control group. |
28296202 |
| rheumatoid arthritis |
|
LDR-PCR |
328 RA patients and 449 healthy controls |
|
mutation |
H19 rs2839698, rs217727, and HOTAIR rs12826786 polymorphisms might not be involved in the genetic background of RA in Chinese |
28314879 |
| cholangiocarcinoma |
|
knockdown |
CCA tissue samples and cell lines |
up-regulated |
expression/mutation |
Cholangiocarcinoma (CCA) is a deadly disease that poorly responds to chemotherapy and radiotherapy and whose incidence has increased worldwide. Furthermore, long noncoding RNAs (lncRNAs) play important roles in multiple biological processes, including tumorigenesis. Specifically, H19, the first discovered lncRNA, has been reported to be overexpressed in diverse human carcinomas, but the overall biological role and clinical significance of H19 in CCA remains unknown. |
28528181 |
| epilepsy |
|
microarray |
epileptic rats |
differential expression |
expression |
H19 has diverse functions related to epileptogenesis |
28564591 |
| middle cerebral artery occlusion |
|
qRT-PCR, knockdown, |
stroke patients compared with healthy controls |
up-regulated |
expression/mutation |
Promotes Neuroinflammation in Ischemic Stroke by Driving Histone Deacetylase 1-Dependent M1 Microglial Polarization. |
28630232 |
| chronic myeloid leukemia |
|
qRT-PCR, qMSP, BSP |
A total of 85 CML patients and 36 healthy donors, bone marrow (BM) |
up-regulated |
epigenetics |
Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia. |
28776669 |
| bladder cancer |
|
microarray, knockdown |
BC tissues and cells |
|
expression |
H19 could increase proliferation, invasion and migration, regulate EMT as well as rearrange cytoskeleton of BC cells in vitro. |
28779971 |
| coronary artery disease |
|
qRT-PCR, |
CAD patients with heart failure compared to those with normal cardiac function |
up-regulated |
expression |
Increased plasma levels of H19 and LIPCAR are associated with increased risk of CAD and may be considered as novel biomarkers for CAD. |
28790415 |
| repeated implantation failure |
|
qRT-PCR,western blot, |
RIF group, control group |
down-regulated |
expression |
To detect the expression level of imprinted gene H19 in the endometrium of patients with repeated implantation failure (RIF) who were undergoing in vitro fertilization and embryo transfer (IVF-ET) or frozen embryo transfer (FET). |
28791461 |
| gastric cancer |
|
qRT-PCR, western blot, knockdown, Gain and loss of function, luciferase reporter assay |
normal (GES-1) and gastric cancer cell lines (SGC-7901, SGC-7901/DDP) , tumor tissues. |
up-regulated |
expression/mutation |
In our study H19 and miR-675 were increased in gastric cancer cell lines and tissues. Overexpression of H19 and miR-675 promoted cell proliferation and inhibited cell apoptosis, whereas knockdown of H19 and miR-675 inhibited these effects |
28848149 |
| metabolic disease |
|
knockdown |
17 long non-coding RNAs (lncRNAs) cultured MC3T3-E1 cells under Rh2 treatments |
up-regulated |
expression/mutation |
Increased expression of lncRNA H19 resulted in osteopontin (OPN) overexpression in Rh2-treated MC3T3-E1 cells. Furthermore, knockdown of lncRNA H19 by specific siRNAs significantly abolished the Rh2-mediated cell proliferation effects. Knockdown of lncRNA H19 also decreased both mRNA and protein levels of OPN in the Rh2-treated cells, which was accomplished by inhibiting histones H3 and H4 acetylation of OPN promoter. Importantly, OPN knockdown fully blocked Rh2 induced MC3T3-E1 cell proliferation. |
28886306 |
| osteosarcoma |
|
|
osteosarcoma cases and cancer-free controls. |
|
mutation |
For the main effect analysis, rs217727 (G>A) was associated with osteosarcoma risk |
28975992 |
| oral squamous cell carcinoma |
|
microarray, |
oral squamous cell |
|
mutation |
It is indicated in this research that rs217727 is statistically correlated with the susceptibility of OSCC. |
28975993 |
| breast cancer |
|
|
|
|
expression |
H19 lncRNA expression was significantly increased in anthracycline-treated and Dox-resistant MCF-7 breast cancer cells |
29190892 |
| colorectal cancer |
|
qRT-PCR, western blot, Knockdown |
tumor tissues, adjacent normal tissues, normal NCM460 cells , colorectal cancer SW480, HCT116 and SW620 cells. |
up-regulated |
expression |
Knock-down H19 expression can inhibit proliferation of colorectal cancer cells |
29260518 |
| multiple myeloma |
|
knockdown |
MM cell lines, sorted CD138+ MM bone marrow tissues |
up-regulated |
expression |
H19 knockdown induced by shRNA transfection significantly inhibited proliferation, viability and colony formation in MM cells, as well as inactivated NF-κB pathway |
29273733 |
| papillary thyroid carcinoma |
|
qRT-PCR |
PTC tissues and PTC cell lines |
down-regulated |
expression |
H19 overexpression reduced PTC cell proliferation and migration. It also inhibited the expression of tumor necrosis factor receptor 2. |
29287713 |
| thyroid cancer |
|
qRT-PCR,western blot |
|
down-regulated |
expression |
Long Noncoding RNA H19 Inhibits Cell Viability, Migration, and Invasion Via Downregulation of IRS-1 in Thyroid Cancer Cells. |
29332545 |
| pancreatic ductal adenocarcinoma |
|
overexpression |
|
|
expression |
Long noncoding RNA H19 derived miR-675 regulates cell proliferation by down-regulating E2F-1 in human pancreatic ductal adenocarcinoma. |
29344285 |
| oral squamous cell carcinoma |
|
qRT-PCR |
OSCC cells |
|
expression |
H19 significantly inhibited OSCC cell proliferation, migration, invasion and epithelial-mesenchymal transition (EMT), and induced apoptosis in vitro; it also suppressed subcutaneous tumor growth in vivo. |
29344674 |
| glioma |
Temozolomide |
Knockdown |
glioma cells |
down-regulated |
expression |
The silencing of LncRNA-H19 decreases chemoresistance of human glioma cells to temozolomide by suppressing epithelial-mesenchymal transition via the Wnt/β-Catenin pathway. |
29391808 |
| glioma |
|
qRT-PCR |
glioma cell |
down-regulated |
expression |
H19 promoted glioma cell proliferation and invasion by negatively regulating miR-152 expression, providing evidence for the potential application of H19 as a biomarker and therapy target for glioma. |
29422115 |
| cholestatic liver
injury |
|
overexpression |
Mdr2-/- mice and cirrhotic patients |
up-regulated |
expression |
Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver
injury in mouse and human. |
29425397 |
| ovarian cancer |
|
knockdown, qRT-PCR, western blot |
Human epithelial ovarian cancer cells (A2780 S and A2780/CP) |
down-regulated |
expression |
These data indicated that VPA negatively regulates the expression of H19 in ovarian cancer cells, which subsequently leads to apoptosis induction, cell proliferation inhibition, and overwhelming to cisplatin resistance. |
29468525 |
| pre-eclampsia |
|
qRT-PCR, western blot |
trophoblast cells |
up-regulated |
expression |
LncRNA-H19, which was up-regulated in PE, reduced cell viability but promoted invasion and autophagy in trophoblast cells, along with activation of the PI3K/AKT/mTOR pathways. |
29522949 |
| squamous cell carcinoma |
|
qRT-PCR |
impedestongue squamous cell carcinoma tissues |
up-regulated |
expression |
H19 facilitates tongue squamous cell carcinoma migration and invasion via sponging miR-let-7 |
29523225 |
| disuse osteoporosis |
|
|
UMR-106 cells |
differential expression |
epigenetics |
LncRNA-H19 and inhibition of the ERK signaling, suggesting a new potential therapeutic target. |
29555308 |
| osteosarcoma |
|
qRT-PCR, western blot |
tumor tissue and adjacent healthy tissue |
up-regulated |
expression |
LncRNA H19 can inhibit migration and invasion of human osteosarcoma cells by inhibiting the nuclear factor-κB pathway. |
29568924 |
| melanoma |
|
qRT-PCR, western blot |
melanoma cells |
down-regulated |
expression |
Downregulation of lncRNA H19 inhibits the migration and invasion of melanoma cells by inactivating the NF-κB and PI3K/Akt signaling pathways |
29568965 |
| growth hormone-secreting pituitary adenomas |
|
qRT-PCR |
invasive GHPAs, |
up-regulated |
expression |
LncRNA H19 might be a target for the study of GHPAs invasion, and a potential index for the diagnosis or prognosis of GHPAs |
29604339 |
| acute myeloid leukemia |
|
qRT-PCR, Loss-of-function, overexpression |
AML patients |
up-regulated |
expression |
Methylation-independent H19 was a prognostic and predictive biomarker in AML, and H19/ID2 played crucial roles in leukemogenesis with potential therapeutic target value. |
29643943 |
| breast cancer |
|
microarray, knockdown |
HCC1934 and iCSCL10A cell lines |
up-regulated |
expression |
H19 was associated with stem cell phenotype in ALDH1-positive breast cancer. H19 regulates CSC and is associated with poor prognosis in breast cancer patients, particularly in triple-negative subtype. |
29693231 |
| acute promyelocytic leukemia |
|
microarray, qRT-PCR |
maturation-resistant APL cell line |
down-regulated |
expression |
This study identifies a new way of telomerase regulation through H19's involvement and thereby reveals a new function for this long non-coding RNA that can be targeted for therapeutic purpose. |
29703210 |
| hepatocellular carcinoma |
|
qRT-PCR, western blot, knockdown |
HCC tissues and cells |
up-regulated |
expression |
Effect of long non-coding RNA H19 on oxidative stress and chemotherapy resistance of CD133+ cancer stem cells via the MAPK/ERK signaling pathway in hepatocellular carcinoma. |
29800569 |
| retinoblastoma |
|
qRT-PCR, western blotting, Knockdown |
retinoblastoma clinical samples and cell lines |
up-regulated |
expression |
LncRNA H19 may serve an important function in tumorigenesis and may be a potential target for therapy and prognosis in retinoblastoma. |
29805578 |
| glioma |
|
knockdown, overexpression, |
glioma U87MG cells |
up-regulated |
expression |
AGPS silencing suppressed the proliferation and migration potential of glioma U87MG cells, and suppressed the expression of the circular RNAs circ-ubiquitin-associated protein 2, circ-zinc finger protein 292 and circ-homeodomain-interacting protein kinase 3, and the long non-coding RNAs H19 imprinted maternally expressed transcript (non-protein coding), colon cancer-associated transcript 1 (non-protein coding) and hepatocellular carcinoma upregulated long non-coding RNA. |
29805677 |
| hypertrophic cardiomyopathy |
|
RNA-Seq, |
cardiac hypertrophy and heart failure tissues |
up-regulated |
mutation |
Significant association between H19 variants and the risk of developing HCM. |
29962225 |
| NT2 embryonal carcinoma |
|
knockdown |
the human PGC-derived EC cell line NTera-2 (NT2) |
down-regulated |
expression |
Analysis of the Paternally-Imprinted DLK1-MEG3 and IGF2-H19 Tandem Gene Loci in NT2 Embryonal Carcinoma Cells Identifies DLK1 as a Potential Therapeutic Target. |
29980981 |
| type 2 diabetes mellitus |
|
PCR-RFLP |
496 T2D patients and 473 non-diabetic and sex-matched controls |
|
expression |
Our findings provided the evidence of significant association between H19 rs217727-TT and MEG3 rs7158663-AA genotypes with T2D usceptibility. |
29981420 |
| melanoma |
|
qRT-PCR, ELISA, western blot, knockdown |
keratinocytes |
down-regulated |
expression |
UVB-inhibited H19 may promote α-MSH secretion by p53 in keratinocytes and then regulate melanocytes melanogenesis through paracrine effects. |
30044001 |
| gastric cancer |
|
overexpression |
GC patients (n=40) compared with a control group consisting of endoscopy-verified GC-free individuals |
up-regulated |
expression |
Higher levels of circulating H19 were identified in GC patients (n=40) compared with a control group consisting of endoscopy-verified GC-free individuals . In conclusion, the present findings identify H19 as potential diagnostic marker in GC. |
30083318 |
| coronary artery disease |
|
qRT-PCR, overexpression, |
50 CAD patients and 50 age and sex-matched healthy controls |
up-regulated |
expression |
Association of Increased Levels of lncRNA H19 in PBMCs with Risk of Coronary Artery Disease. |
30124004 |
| colorectal cancer |
|
western blot, overexpression |
colorectal cancer (CRC) cells, |
up-regulated |
expression |
H19 may promote metastasis and invasion in colorectal cancer by activating the RAS-MAPK signaling pathway. |
30127936 |
| gastric cancer |
|
microassay, knockdown |
gastric cancer cells, AGS and SGC7901 cell lines |
down-regulated |
expression |
Metformin has a profound antitumor effect on gastric cancer cells, and H19 is a key component in the process of metformin suppressing gastric cancer cell invasion. |
30192003 |
| triple-negative breast cancer |
paclitaxel |
overexpression, knockdown, |
paclitaxel-resistant cells than that paclitaxel-sensitive cells |
up-regulated |
expression |
Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway. |
30244121 |
| breast cancer |
|
colony-formation assay |
breast cancer cells |
up-regulated |
expression |
The modulation of lncRNA expression and inhibition of NF-κB activation by bharangin may contribute to its anti-carcinogenic activities. |
30251663 |
| age-related cataract |
|
RNA-Seq, qRT-PCR, luciferase reporter, knockdown, |
the nuclear ARC lens capsules |
up-regulated |
expression |
H19 regulates HLECs function through miR-675-mediated CRYAA expression |
30286462 |
| glioma |
|
immunoblotting, Luciferase reporter, qRT-PCR, knockdown, overexpression |
glioma cells |
up-regulated |
expression |
H19 confers TMZ resistance through activating NF-κB signaling and may represent a novel therapeutic target for TMZ-resistant gliomas. |
30323617 |
| hepatocellular carcinoma |
|
Overexpression, mimics |
HCC cells |
up-regulated |
expression |
H19/miR-326/TWIST1 axis was involved in HCC development and can indicate a novel HCC target. |
30362512 |
| pancreatic ductal adenocarcinoma |
|
overexpression, knockdown |
PDAC cells |
down-regulated |
expression |
H19 plays critical roles in the CSC self-renewal and cell adhesion of PDAC that lead to invasion and metastasis. |
30410672 |
| cholestasis |
|
ISH, immunofluorescence (IF) |
human primary biliary cholangitis (PBC) , primary sclerosing cholangitis (PSC) liver specimens |
up-regulated |
expression |
H19RNA is localized in HNF4α+ periportal hepatocytes, SOX9+ ductal progenitor cells, and F4/80+ Kupffer cells but not in CK19+ cholangiocytes and desmin+ stellate cells in cholestatic livers. |
30411082 |
| hepatocellular carcinoma |
|
qRT-PCR, |
HCC tissues |
down-regulated |
expression |
Development of a GeXP-Based Multiplex RT-PCR Assay for Detection of Long Noncoding RNA in Hepatocellular Carcinoma. |
30423146 |
| gastric cancer |
|
qRT-PCR, |
the plasma samples of GC patients and controls. |
up-regulated |
expression |
H19, MEG3 and miR-675-5p expression levels could provide a potential diagnostic panel for GC. |
30447342 |
| pancreatic ductal adenocarcinoma |
|
luciferase reporter, RNA immunoprecipitation, knockdown, overexpression |
PDAC tissues |
up-regulated |
expression |
LncRNA H19/miR-194/PFTK1 axis modulates the cell proliferation and migration of pancreatic cancer. |
30474270 |
| breast cancer |
|
PCR-RFLP |
150 BC patients and 100 cancer-free subjects East Azerbaijan Province of Iran |
down-regulated |
expression |
Association of the study between LncRNA-H19 gene polymorphisms with the risk of breast cancer. |
30485527 |
| ER+ breast cancer |
|
Gain and loss of function, |
Breast Cancer Cells, ETR cell models |
up-regulated |
expression |
Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells |
30497079 |
| breast cancer |
Tamoxifen |
qRT-PCR, western blot, knockdown, |
breast cancer cell |
up-regulated |
expression |
LncRNA H19 expression level manipulated breast cancer cell proliferation both in parental breast cancer cell lines and tamoxifen-resistant cell lines. Knockdown of lncRNA H19 elevated tamoxifen sensitivity for promoting cell growth and inhibiting apoptosis in tamoxifen-resistant breast cancer cells. Moreover, knockdown of H19 inhibited Wnt pathway and epithelia-mesenchymal transition in tamoxifen-resistance breast cancer cells. |
30519041 |
| non-small cell lung cancer |
gefitinib resistance |
qRT-PCR, knockdown, |
NSCLC cells |
up-regulated |
expression |
H19 promoted gefitinib resistance of NSCLC cells by packaging into exosomes. |
30542738 |
| bladder cancer |
|
qRT-PCR, |
serum of BC patients when compared to healthy people and benign disease patients. |
up-regulated |
expression |
Detection of serum exosomal H19 shed light on using exosomal lncRNAs as a noninvasive diagnostic and prognostic biomarker for BC patients. |
30576305 |
| multiple myeloma |
bortezomib（BTZ） |
overexpression, |
the serum of MM patients |
up-regulated |
expression |
H19 reduced cell sensitivity to the chemotherapeutic drug BTZ by working as a miRNA sponge to inhibit the expression of miR-29b-3p,enhance MCL-1 transcriptional translation and inhibit apoptosis. |
30728351 |
| lung adenocarcinoma |
|
mimic, knockdown, |
lung adenocarcinoma tissues and four human lung adenocarcinoma cell lines |
up-regulated |
expression |
LncRNA H19 promotes viability and epithelial-mesenchymal transition of lung adenocarcinoma cells by targeting miR-29b-3p and modifying STAT3. |
30747209 |
| atherosclerosis |
|
western blot, dual-luciferase reporter, knockdown, overexpression, |
vascular smooth muscle cells(VSMC) and human umbilical veendothelial cells (HUVECs), An ischemic stroke mouse model, |
up-regulated |
expression |
Long Noncoding RNA-H19 Contributes to Atherosclerosis and Induces Ischemic Stroke via the Upregulation of Acid Phosphatase 5. |
30778327 |
| spontaneous abortion |
|
knockdown, rescue experiments, qRT-PCR, Luciferase reporter, western blot, |
the HTR-8/SVneo cell line |
down-regulated |
expression |
H19 regulates trophoblastic spheroid adhesion by competitively binding to let-7. |
30780128 |
| multiple myeloma |
hypoxia (1% O₂) |
western blot, knockdown, overexpression, |
MM cell lines (RPMI and MM1.S) exposed to normoxia or hypoxia (1% O₂) |
up-regulated |
expression |
Moreover, adhesion assays demonstrated that lncH19 silencing abrogates the increased adhesion on stromal cells induced by the hypoxic condition. |
30781795 |
| breast cancer |
|
qRT-PCR |
plasma samples of 63 BC patients and 10 healthy women |
up-regulated |
expression |
Interplay of lncRNA H19/miR-675 and lncRNA NEAT1/miR-204 in breast cancer. |
30803129 |
| diabetic nephropathy |
|
western blot, qRT-PCR, Luciferase reporter assays, |
the DN(+) group |
up-regulated |
expression |
A negative feedback loop of H19/miR-675/EGR1 is involved in diabetic nephropathy by downregulating the expression of the vitamin D receptor. |
30815865 |
| papillary thyroid carcinoma |
|
qRT-PCR, western blot, knockdown |
PTC tissue samples, paracancerous tissue samples, PTC cells, Overexpression |
up-regulated |
expression |
Long noncoding RNA H19 is a critical oncogenic driver and contributes to epithelial-mesenchymal transition in papillary thyroid carcinoma. |
30881130 |
| coronary artery disease |
|
overexpression, qRT-PCR, ELISA, western blot |
serum |
up-regulated |
expression |
H19 overexpression participates in the pathogenesis of CAD by increasing the expression level of TGF-β1, and H19 expression level may serve as a diagnostic marker for CAD. |
30892430 |
| polycystic ovary syndrome |
|
qRT-PCR, |
peripheral blood leukocytes from patients with PCOS |
up-regulated |
expression |
LncRNA H19 is associated with PCOS, suggesting that elevated lncRNA H19 levels are a risk factor for PCOS. |
30982795 |
| cholestatic liver injury |
|
qRT-PCR, western blot, immunohistochemistry, |
Mouse and human primary sclerosing cholangitis (PSC)/primary biliary cholangitis (PBC) liver samples |
up-regulated |
expression |
Cholangiocyte-derived exosomal LncRNA H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis. |
30985008 |
| abdominal aortic aneurysm |
|
qRT-PCR, overexpression, rescue experiment, Luciferase reporter assays, |
human and mouse AAA tissue samples. |
up-regulated |
expression |
H19/let-7a/IL-6 inflammatory pathway in AAA formation, which offers a new potential therapeutic strategy for AAA. |
30991034 |
| urothelial cell carcinoma |
|
qRT-PCR |
Urothelial cell carcinoma (UCC) tissue |
|
expression |
H19 polymorphisms may be applied as a marker or therapeutic target in UCC treatment. |
31013794 |
| triple-negative breast cancer |
|
overexpression |
tumor tissues of patients with triple-negative breast cancer (TNBC) |
up-regulated |
expression |
lncRNA PTCSC3 inhibits TNBC cell proliferation by downregulating lncRNA H19. |
31026090 |
| Tricho-Dento-Osseous (TDO) syndrome |
|
rescue studies, CHIP, |
hDPCs |
up-regulated |
mutation |
DLX3 epigenetically regulates odontoblastic differentiation of hDPCs through H19/miR-675 axis. |
31029881 |
| ischemic stroke |
|
Microarray, qRT-PCR |
550 IS cases and 550 controls |
up-regulated |
mutation |
Association of long noncoding RNA H19 polymorphisms with the susceptibility and clinical features of ischemic stroke in southern Chinese Han population. |
31041585 |
| neuropathic pain |
|
qRT-PCR |
Schwann cells |
up-regulated |
expression |
H19 lncRNA increase in Schwann cells might be involved in neuropathic pain. |
31061251 |
| cirrhosis |
hypoxia stress |
qRT-PCR, western blot, luciferase reporter gene detection system, mimics, overexpression |
hepatic sinusoidal endothelial cells (HHSEC) |
up-regulated |
expression |
Long non-coding RNA H19, a negative regulator of microRNA-148b-3p, participates in hypoxia stress in human hepatic sinusoidal endothelial cells via NOX4 and eNOS/NO signaling. |
31082428 |
| uterine leiomyoma |
TET3 |
genome-wide transcriptome and methylation profiling analyses |
hyperplastic smooth muscle cells |
up-regulated |
expression |
H19 promotes expression of MED12, HMGA2, and key ECM-remodeling genes via multiple mechanisms including a new class of epigenetic modification by TET3. |
31089260 |
| glioma |
|
qRT-PCR, western blot |
glioma tissues, para-carcinoma tissues, and glioma cell lines |
up-regulated |
expression |
Long non-coding RNA H19 regulates the development of gliomas through the Wnt/β-catenin signaling pathway. |
31173296 |
| lung cancer |
|
qRT-PCR, western blot, overexpression |
A549 cells |
up-regulated |
expression |
Long non-coding RNA H19 promotes the proliferation and invasion of lung cancer cells and regulates the expression of E-cadherin, N-cadherin, and vimentin. |
31190899 |
| hypoxia/reoxygenation injury |
chloroquine |
knockdown |
Hep G2 and HCCLM3 cells |
up-regulated |
expression |
The long non-coding RNA H19 induces hypoxia/reoxygenation injury by up-regulating autophagy in the hepatoma carcinoma cells. |
31196153 |
| colorectal cancer (CRC) patients with type 2 diabetes (T2DM) |
|
qRT-PCR |
CRC tissues |
down-regulated |
expression |
the expression of H19 was significantly lower in CRC patients with T2DM compared with CRC patients without T2DM |
31232113 |
| type 2 diabetes mellitus |
|
qRT-PCR |
CRC tissues |
down-regulated |
expression |
the expression of H19 was significantly lower in CRC patients with T2DM compared with CRC patients without T2DM |
31232113 |
| anaplastic thyroid carcinoma |
|
qRT-PCR, knockdown, overexpression |
ATC tissues |
up-regulated |
expression |
Targeted inhibition of long non-coding RNA H19 blocks anaplastic thyroid carcinoma growth and metastasis. |
31299871 |
| acute myocardial infarction |
|
qRT-PCR |
peripheral blood mononuclear cells, blood sample |
up-regulated |
expression |
lncRNA H19, MIAT and MALAT1 were significantly higher in AMI patients than in healthy control |
31302423 |
| papillary thyroid carcinoma |
|
qRT-PCR |
PTC tissues, BNT tissues |
down-regulated |
expression |
H19 may serve as a potential predictor of poor prognoses in patients with PTC. |
31403942 |
| thyroid cancer |
|
qRT-PCR, knockdown, western blot |
TC tissues, FTC-133 and TPC-1 TC cells |
up-regulated |
expression |
Long non-coding RNA H19 knockdown inhibits the cell viability and promotes apoptosis of thyroid cancer cells through regulating the PI3K/AKT pathway. |
31410148 |
| prostate cancer |
Estrogen and hypoxia |
qRT-PCR, western blot, overexpression, knockdown, immunofluorescence assay |
PCa cells |
down-regulated |
expression |
estrogen and hypoxia transcriptionally regulate, via H19, cell adhesion molecules redirecting metastatic dissemination from EMT to a β integrin-mediated invasion. |
31426484 |
| colorectal cancer |
|
qRT-PCR |
sera samples |
up-regulated |
expression |
HOTAIR and H19 expression levels are upregulated in Egyptian CRC patients, and therefore can be considered noninvasive diagnostic biomarkers with high sensitivity and specificity. |
31433231 |
| esophageal squamous cell cancer |
|
RNA in situ hybridization, |
tumor and adjacent non-tumor tissues |
up-regulated |
expression |
High level of lncRNA H19 expression is associated with shorter survival in esophageal squamous cell cancer patients. |
31551175 |
| colon cancer |
Ferrochelatase (FECH) ;H2O2 |
qRT-PCR, knockdown, western blot |
normal fibroblasts, human Caco-2 colon cancer cells |
up-regulated |
expression |
loss of FECH is protective against colon cancer tumorigenesis in vitro and this effect could possibly be mediated through inhibition of H19. |
31602323 |
| rectal cancer |
5‑fluorouracil |
microarray,qRT-PCR, |
cultured colorectal cancer cells, resected tissues of rectal cancer treated with NAC, biopsy samples |
up-regulated |
expression |
changes in H19 and UCA1 expression may be considered for predicting the susceptibility to 5FU‑based NAC in rectal cancer. |
31638183 |
| breast cancer |
neoadjuvant chemotherapy (NAC) |
qRT-PCR, |
blood plasma of patients with BC |
down-regulated |
expression |
Only H19 was associated with patients' characteristics, and with the response to NAC.H19, but not MALAT1 and GAS5, may be a useful marker of response to NAC in BC. |
31640083 |
| pre-eclampsia |
|
qRT-PCR, |
placentas |
up-regulated |
mutation |
the H19 rs2107425 polymorphism was associated with a higher risk of PE and increased H19 mRNA expression. The promoter hypermethylation of H19 gene was associated with a lower risk of PE and decreased H19 mRNA expression. |
31769935 |
| gastric cancer |
Helicobacter pylori (H. pylori) |
qRT-PCR, ELISA, western blot, overexpression |
GC tissues and cells |
up-regulated |
expression |
LncRNA H19 promotes H. pylori-induced GC cell growth via enhancing NF-κB-induced inflammation |
31787851 |
| minimally invasive follicular thyroid carcinoma |
|
qRT-PCR |
patients with MI-FTC |
down-regulated |
expression |
Patients with low H19 expression showed a poorer outcome in MI-FTC patients. |
31791180 |
| nonalcoholic fatty liver disease |
|
overexpression |
hepatocytes |
up-regulated |
expression |
H19 promoted hepatic steatosis by up-regulating both mTORC1 signalling axis and MLXIPL transcriptional network. |
31809000 |
| gastrointestinal stromal tumor |
imatinib |
qRT-PCR |
FFPE tissue specimens from 40 surgically resected and metastatic GIST patients |
up-regulated |
expression |
The percentage of both H19 and MALAT1 upregulation was significantly higher in patients with time to progression (TTP) < 6 months as compared to patients with TTP > 6 months. |
31827510 |
| rheumatoid arthritis |
|
qRT-PCR |
peripheral blood mononuclear cells |
down-regulated |
expression |
The expression levels of H19, GAS5 and linc0597 were down-regulated in PBMCs of RA patients, |
31905737 |
| cholestatic liver injury |
|
|
Kupffer cells |
up-regulated |
expression |
Cholangiocyte-Derived Exosomal lncRNA H19 Promotes Macrophage Activation and
Hepatic Inflammation under Cholestatic Conditions. |
31940841 |
| ischemic stroke |
|
knockdown |
|
up-regulated |
expression |
LncRNA H19 inhibition increased IGF1R expression and activated IGF1 mediated mTOR pathway. |
31991123 |
| breast cancer |
doxorubicin |
overexpression, knockdown |
DOX-resistant breast cancer cells |
up-regulated |
expression |
H19 could be delivered by exosomes to sensitive cells, leading to the dissemination of DOX resistance. |
31994191 |
| type 2 diabetes mellitus |
|
qRT-PCR |
plasma |
up-regulated |
expression |
Circulating long noncoding RNAs H19 and GAS5 are associated with type 2 diabetes but not with diabetic retinopathy |
31999937 |
| breast cancer |
|
knockdown, overexpression, qRT-PCR, western blot |
T-47D cells |
up-regulated |
expression |
H19/let‑7/Lin28 ceRNA network mediates autophagy inhibiting epithelial‑mesenchymal transition in breast cancer. |
32124962 |
| acute lymphoblastic leukemia |
|
microarray, Overexpression, Knockdown, qRT-PCR, |
T-ALL cells, ETP-ALL cells, prostate cancer cells |
up-regulated |
epigenetics |
PIM kinases control the level of lncRNA H19, which in turn modifies stem cell gene transcription regulating tumor growth |
32146726 |
| glioma |
|
SNP Selection and Genotyping, Haplotype Analysis |
glioma patients and cancer-free subjects |
differential expression |
mutation |
Overall, carriers of the rs3741219 AG or GG genotype of H19 have a decreased susceptibility to glioma, but polymorphisms in this gene are not related to prognosis. |
32155588 |
| chronic myeloid leukemia |
|
RNA pulldown, overexpression |
CML cell lines |
down-regulated |
expression |
Co-overexpression of H19 and PCBP1, FUS, miR-19a-3p, and miR-106b-5p decreases the inhibitory effect of H19 in CML. |
32160707 |
| breast cancer |
|
qRT-PCR |
breast cancer serum-derived |
up-regulated |
expression |
The median serum exosomal H19 levels were significantly lower in post-operative than that in the pre-operative patients (P < 0.001). |
32273726 |
| bronchopulmonary dysplasia |
|
qRT-PCR, overexpression |
BPD and normal lung tissues |
up-regulated |
expression |
lncRNA H19 contributes to the progression of BPD by regulating MAPK signaling pathway |
32308025 |
| fetal growth restriction |
|
qRT-PCR |
paraffin-embedded tissues |
down-regulated |
expression |
This study highlights the potential importance of regulatory events mediated by H19 in SGA placentas without histopathological abnormalities in late pregnancy. |
32323427 |
| oral squamous cell carcinoma |
|
ARMS-PCR, |
pathologically diagnosed patients with new-onset OSCC and healthy controls. |
up-regulated |
mutation |
rs217727 and OSCC susceptibility were statistically correlated in the Iranian population. |
32337223 |
| breast cancer |
doxorubicin |
western blot, knockdown, qRT-PCR |
chemotherapy-resistant breast cancer tissues and doxorubicin-resistant breast cancer cell lines |
up-regulated |
expression |
Our findings revealed that H19 plays a leading role in breast cancer chemoresistance development, mediated mainly through a H19-PARP1 pathway. |
32345117 |
| type 2 diabetes mellitus |
|
qRT-PCR, western blot |
|
up-regulated |
expression |
Altered levels of MALAT1 and H19 derived from serum or serum exosomes associated with type-2 diabetes. |
32346662 |
| Arterial calcification |
|
Knockdown, qRT-PCR, western blot, |
Vascular Smooth Muscle Cells |
up-regulated |
expression |
This finding not only reveal a novel function of lncRNA H19, but also provides a new opinion on the role of lncRNA H19 which participant in the Runx2 regulatory pathway in AC and can be a new indication for the diagnosis and treatment of AC at an early time. |
32355545 |
| Parkinson's disease |
MPP+ |
overexpression |
human neuroblastoma cells |
down-regulated |
expression |
LncRNA H19 could attenuate neurons apoptosis in MPTP-induced PD mice as well as MPP+ treated neuroblastoma cells through regulating miR-585-3p/PIK3R3. |
32356199 |
| prostate cancer |
androgen stimulation via dihydrotestosterone (DHT) or AR blockage via enzalutamide |
qRT-PCR |
Pca cells. |
down-regulated |
expression |
Restorative effect of enzalutamide on decreased H19 expression induced by androgen stimulation was not observed in exosomes. |
32356434 |
| osteoarthritis |
|
qRT-PCR, RNA-seq |
|
up-regulated |
expression |
The possible underlying molecular mechanisms, which remain to be confirmed, are their likely influence on the expression levels of the lncRNA H19 and MEG3, which in turn alters the expression level of their target miRNAs. |
32364812 |
| cardiovascular disease |
hyperglycemic conditions;TNF-α |
|
endothelial cells (ECs) of human atherosclerotic coronary arteries. |
up-regulated |
expression |
H19/TET1 axis promotes TGF-β signaling linked to endothelial-to-mesenchymal transition. |
32374060 |
| Interaction |
| Interaction target |
Level of interaction |
Type of interaction |
Methods |
Description |
PMID |
| YB-1 |
RNA-Protein |
binding |
ChIRP, RIP, qRT-PCR, RNA-EMSA |
we identified Y-box-binding protein (YB)-1, a suppressor of Collagen 1A1, as an interacting protein of H19. |
31588235
|
| miR-106a |
RNA-RNA |
binding |
qRT-PCR, overexpression |
miR-106a overexpression experiments confirmed that miR-CLIP captured functional targets, including H19, a long noncoding RNA that is expressed during skeletal muscle cell differentiation. |
25531890
|
| 4E-BP1 |
RNA-Protein |
binding |
N/A |
H19 could block mTORC1-mediated 4E-BP1 phosphorylation without affecting S6K1 activation. At the molecular level, H19 interacted with 4E-BP1 at the TOS motif and competitively inhibited 4E-BP1 binding to Raptor. |
30397197
|
| 4E-BP1 |
RNA-Protein |
regulation |
western blot |
Exosomal H19 inhibits the growth of distal pituitary tumors through inhibiting 4E-BP1 phosphorylation. |
31369093
|
| ADH3 |
RNA-Protein |
regulation |
N/A |
The inhibition of ADH3 completely abrogated the lncRNA-H19 mediated retinoic acid signals and HSC activation. |
32304991
|
| c-Myc |
DNA-TF |
regulation |
ChIP |
H19 was a direct transcriptional target of c-Myc. |
26482621
|
| DNMT3B |
RNA-Protein |
regulation |
N/A |
H19/SAHH axis epigentically regulates odontogenic differentiaiton of hDPSCs by inhibiting the DNA methyltransferase 3B (DNMT3B)-mediated methylation of DLX3. |
30165103
|
| DNMT3B |
RNA-Protein |
regulation |
western blot |
DNMT3B binds to the Beclin1 promoter region and the knockdown of H19 increases this binding. |
31340867
|
| EIF4A3 |
RNA-Protein |
binding |
N/A |
eIF4A3 as an RNA-binding protein that binds to H19. Combining eIF4A3 with H19 obstructed the recruitment of eIF4A3 to the cell-cycle gene mRNA. |
26989025
|
| EZH2 |
RNA-Protein |
binding |
N/A |
H19 regulated EZH2 expression by suppressing the activity of mir-630, which is a repressor of EZH2 and interacts with H19 in a sequence-specific manner. |
27040767
|
| EZH2 |
RNA-Protein |
regulation |
N/A |
H19 was further confirmed to suppress the promoter activity of BIK by recruiting EZH2 and by trimethylating the histone H3 at lysine 27. |
27845892
|
| EZH2 |
RNA-Protein |
binding |
FISH, RIP, ChIP |
H19 promoted HIF-1α histone H3K4me3 methylation and increased HIF-1α expression by recruiting EZH2. |
30458806
|
| H1.3 |
DNA-Protein |
regulation |
western blot |
H1.3 dramatically inhibits H19 expression, which contributes to the suppression of epithelial ovarian carcinogenesis. |
25205099
|
| HIF-1α |
DNA-TF |
regulation |
ChIP |
Hif-1α induced H19 transcription through directly binding to the H19 promoter. |
28327666
|
| HIF-1α |
DNA-TF |
regulation |
N/A |
H19-dependent apoptosis mechanisms in SMCs appeared to be independent of mir-675, which is embedded in the first exon of the H19 gene. A customized transcription factor array identified hypoxia-inducible factor 1-alpha (HIF1α) as the main downstream effector. Increased SMC apoptosis was associated with cytoplasmic interaction between H19 and HIF1α and sequential p53 stabilization. |
29669788
|
| HIF-1α |
DNA-TF |
regulation |
N/A |
the knockdown of H19 slowed down tumor growth, promoted apoptosis and upregulated mir-20b-5p expression but lowered the expressions of HIF-1α, PCNA and AXL in vivo. |
31411527
|
| hnRNPU |
RNA-Protein |
binding |
N/A |
Western blot analysis was performed to determine the specific association between hnRNP U and H19. |
26801864
|
| HuR |
RNA-Protein |
binding |
N/A |
H19 interacts with HuR and regulates the intestinal epithelial barrier function via the H19-encoded mir-675 by altering ZO-1 and E-cadherin expression posttranscriptionally. |
26884465
|
| IGF2 |
RNA-DNA |
regulation |
N/A |
H19 is an imprinted maternally expressed gene influencing IGF2 expression, whose transcript is a long noncoding (lnc) RNA of unknown biological function harboring the mir-675. |
22527881
|
| IGF2 |
RNA-DNA |
regulation |
N/A |
The mean percentage of H19 methylation (eight CpG sites), IGF2 methylation (five CpG sites) and SNRPN methylation (nine CpG sites) did not differ significantly. |
29976200
|
| IMP |
RNA-Protein |
binding |
N/A |
Human h19 rna contains four attachment sites for the oncofetal igf-ii mrna-binding protein (imp) |
10875929
|
| IMP3 |
RNA-Protein |
regulation |
N/A |
Imp-3 protein associates with igf-ii leader-3 and leader-4 mrnas and h19 rna |
15753088
|
| KSRP |
RNA-Protein |
binding |
N/A |
KSRP directly binds to H19 in the cytoplasm of undifferentiated multipotent mesenchymal C2C12 cells |
25385579
|
| let-7 |
RNA-RNA |
binding |
N/A |
Acting as a molecular sponge, H19 inhibits microRNA (miRNA) let-7. |
25399420
|
| let-7 |
RNA-RNA |
regulation |
N/A |
Downregulation of H19 leads to reduced migration and invasion of extravillous trophoblast (EVT) cells in vitro. This is consistent with reduced trophoblast invasion that has been observed in FGR. Genome-scale transcriptome profiling of EVT cells reveals significantly decreased expression of the type III TGF-β receptor (TβR3) following H19 knockdown. Decreased TβR3 expression is also seen in FGR placentae. TβR3 repression decreases EVT cell migration and invasion, owing to impaired TGF-β signaling through a non-canonical TGF-β signaling pathway. Further, we identify TβR3 as a novel regulatory target of microRNA let-7. |
27223264
|
| let-7 |
RNA-Protein |
binding |
N/A |
H19 promoted let-7 expression by decreasing PTBP1's expression level and its binding to the let-7 precursors in cholestasis. |
30778047
|
| let-7 |
RNA-RNA |
binding |
N/A |
LncRNA H19/mir-let-7 axis participates in the regulation of ox-LDL-induced endothelial cell injury via targeting periostin. |
31054453
|
| let-7 |
RNA-RNA |
binding |
western blot |
Mechanistically, H19 competitively sponged let-7 genes and therefore up-regulated HRAS, which consequently contributed to its oncogenic activity in nasopharyngeal carcinomas. |
31556327
|
| let-7a |
RNA-RNA |
binding |
RIP |
H19 and HULC, up-regulated by oxidative stress, regulate CCA cell migration and invasion by targeting IL-6 and CXCR4 via ceRNA patterns of sponging let-7a/let-7b and mir-372/mir-373. |
27809873
|
| let-7a |
RNA-RNA |
regulation |
N/A |
This study demonstrated that increased lncRNA H19 and decreased miRNA let7a expression levels are associated with poor prognosis in TC patients. An inverse relationship between lncRNA H19 and miRNA let7a expression levels was exhibited. |
28655518
|
| let-7b |
RNA-RNA |
binding |
RIP |
H19 and HULC, up-regulated by oxidative stress, regulate CCA cell migration and invasion by targeting IL-6 and CXCR4 via ceRNA patterns of sponging let-7a/let-7b and mir-372/mir-373. |
27809873
|
| let-7b |
RNA-RNA |
binding |
dual-luciferase reporter assay, RIP |
H19 acts as a competitive endogenous RNA against let-7b. |
32069774
|
| let-7c |
RNA-RNA |
regulation |
N/A |
H19 may function as a competing endogenous RNA to regulate HER2 expression by sequestering let-7c in GC cells. |
29207111
|
| MACC1 |
RNA-Protein |
regulation |
N/A |
MACC1 protein targeted by H19 was upregulated as well as the downstream signaling proteins including epidermal growth factor receptor (EGFR), β-catenin, extracellular-signal-regulated kinase 1/2 (ERK1/2). Inhibited the expression of EGFR or ERK1/2 significantly decreased the migration and invasion of tumor cells. |
27607135
|
| macroH2A |
RNA-Protein |
binding |
N/A |
H19 interacts with macroH2A, an essential regulator of CDK8 gene transcription. |
27789274
|
| MBD1 |
RNA-Protein |
binding |
N/A |
Paternally expressed genes (PEG) were largely absent from BAT and we demonstrated that H19 recruits PEG-inactivating H19-MBD1 complexes and acts as BAT-selective PEG gatekeeper. |
30190464
|
| miR-103a |
RNA-RNA |
binding |
luciferase reporter assay, western blot, RNA pulldown |
H19 directly interacted with and promoted the degradation of miR-103a. |
32362074
|
| miR-106-5p |
RNA-RNA |
regulation |
N/A |
we found that TIMP2 was directly regulated by miR-106-5p. Using chondrocyte cultures, the enhanced cellular proliferation and migration during exosome-mediated cartilage repair was linked to the exosomal lncRNA H19-mediated regulation of the miR-106b-5p/TIMP2 axis. |
32248331
|
| miR-106a-5p |
RNA-RNA |
binding |
N/A |
We also demonstrated that lncRNA H19 may function as the sponge of miR-106a-5p to up-regulate E2F3 expression, and consequently promote the glucose metabolism and growth of melanoma. |
29350287
|
| miR-106a-5p |
RNA-RNA |
binding |
N/A |
miR-106a-5p was a direct target of H19. |
31894109
|
| miR-106a-5p |
RNA-RNA |
binding |
western blot, ELISA |
We demonstrated the H19/miR-106a-5p/VEGFA regulatory axis in EVT. |
32107606
|
| miR-106b-5p |
RNA-RNA |
binding |
N/A |
H19 acts as a miRNA-106b-5p sponge and thus impairs the function of miRNA-106b-5p on its target gene, TDRG1. |
30430771
|
| miR-106b-5p |
RNA-RNA |
binding |
N/A |
LncRNA H19 may promote chondrocyte proliferation and migration and inhibit matrix degradation in OA possibly by targeting the mir-106b-5p/TIMP2 axis. |
32248331
|
| miR-107 |
RNA-RNA |
regulation |
luciferase reporter assay, ChIP |
The expression of miR-107 increased or decreased with the overexpression and knockdown of H19, respectively. The number of cells in G2/M stage decreased significantly with the knockdown of H19 and miR-107 compared with the control group. |
26722426
|
| miR-107 |
RNA-RNA |
binding |
N/A |
H19 regulates NF1 expression through competitive binding to microRNA-107, thereafter participating in NSCLC development. |
30280776
|
| miR-124-3p |
RNA-RNA |
binding |
N/A |
From these results, we can infer that in endometriosis both miR-124-3p and ITGB3 operate as downstream effector proteins in the H19-signaling pathway. LncRNA-H19 regulates cell proliferation and invasion of ectopic endometrium by targeting ITGB3 via modulating miR-124-3p. |
31085188
|
| miR-130a |
RNA-RNA |
binding |
N/A |
H19 negatively regulated the expression of miR-130a via acting as a molecular sponge for miR-130a. |
30900425
|
| miR-130a |
RNA-RNA |
binding |
ELISA, western blot |
H19 could bind to miR-130a, and miR-130a could directly inhibit PPARγ expression. |
31064820
|
| miR-130a-3p |
RNA-RNA |
binding |
RIP |
H19 and SOX4 are both direct target of miR-130a-3p. H19 could compete with SOX4 via sponging miR-130a-3p. |
30282068
|
| miR-130b |
RNA-RNA |
regulation |
western blot |
we speculated that miR-130b was a target of H19 in ox-LDL-treated Raw264.7 cells. The adding of LncRNA H19 abolished the facilitating effect of miR-130b inhibitor on adipogenesis and inflammation response by up-regulating the expression of miR-130b. |
29172088
|
| miR-130b-3p |
RNA-RNA |
binding |
N/A |
LncRNA-H19 act as an endogenous 'sponge', which binds directly to miR-130b-3p and therefore inhibits its activity on Dsg1. |
29192645
|
| miR-138 |
RNA-RNA |
regulation |
western blot, RIP |
by using bioinformatics study and RNA immunoprecipitation combined with luciferase reporter assays, we demonstrated that H19 functioned as a competing endogenous RNA (ceRNA) for miR-138 and miR-200a, antagonized their functions and led to the de-repression of their endogenous targets Vimentin, ZEB1, and ZEB2, all of which were core marker genes for mesenchymal cells |
26068968
|
| miR-138 |
RNA-RNA |
regulation |
N/A |
miR-138 was identified as a direct target of H19 and SOX4 |
31217890
|
| miR-138 |
RNA-RNA |
binding |
N/A |
miR-138 acted as a target of H19 as detected byluciferase reporter assays. |
31777264
|
| miR-138-5p |
RNA-RNA |
regulation |
western blot, RIP, RNA pulldown |
Remarkably, luciferase reporter assay suggested that H19 negatively regulated miR-138-5p expression and p65 was identified as a target of miR-138-5p. |
32114772
|
| miR-1-3p |
RNA-RNA |
binding |
N/A |
miR-1-3p directly bound to H19 and the CCL2 3'UTR. |
32371379
|
| miR-140 |
RNA-RNA |
binding |
N/A |
The lncRNA H19 interacts with miR-140 to modulate glioma growth by targeting iASPP. |
27693036
|
| miR-140 |
RNA-RNA |
regulation |
N/A |
Moreover, the expression of H19 was negatively correlated with the expression of miR-140 in IPF tissues. |
30988156
|
| miR-140 |
RNA-RNA |
binding |
N/A |
H19 exerted its function via the modulation of H19/mir-140/HE4 in hyperglycemia with α-Mangostin. |
31362245
|
| miR-140-5p |
RNA-RNA |
binding |
luciferase reporter assay, RIP |
MiR-140-5p was confirmed as a target of H19. |
32345782
|
| miR-141 |
RNA-RNA |
regulation |
N/A |
MiR-141 binds to H19 in a sequence specific manner, and suppresses H19 expression and functions including proliferation and invasion. MiR-141 could also regulate H19 target genes and miR-141 inhibitor restores H19 siRNA function, while H19 regulates miR-141 target gene ZEB1. |
26160158
|
| miR-141 |
RNA-RNA |
binding |
western blot |
H19 competitively bound to miR-141 and prevented SPAG9 from miRNA-mediated degradation, thus significantly elevating phosphorylated levels of p38 and JNK and facilitating the committed differentiation of SCAPs. |
30755596
|
| miR-148a-3p |
RNA-RNA |
regulation |
western blot |
Metformin Protects against Oxidative Stress Injury Induced by Ischemia/Reperfusion via Regulation of the lncRNA-H19/miR-148a-3p/Rock2 Axis lncRNA-H19 altered OGD/R-induced oxidative stress by modulating miR-148a-3p to increase Rock2 expression. |
31934270
|
| miR-148b-3p |
RNA-RNA |
binding |
N/A |
long non-coding RNA H19 positively regulated dimethylarginine dimethylaminohydrolase-1 expression via sponging miR-148b-3p. |
31503013
|
| miR-152 |
RNA-RNA |
binding |
N/A |
H19 act as an endogenous sponge by directly binding to miR-152. miR-152 directly targeted DNMT1 and was regulated by H19. |
28544374
|
| miR-152-3p |
RNA-RNA |
regulation |
western blot |
Dual luciferase reporter assay showed H19 targeted miR-152-3p to promote BRD4 expression. |
31712391
|
| miR-152-3p |
RNA-RNA |
binding |
N/A |
The fibroblasts were cocultured with lncRNA H19-transfected MSCs and MSC-derived exosomes to assess the effect of the lncRNA H19/miR-152-3p/PTEN axis on the biological activities and inflammation in fibroblasts. |
31958697
|
| miR-15b |
RNA-RNA |
binding |
western blot, luciferase reporter assay |
MiR-15b interacted with H19 and CDC42 3'-UTR. H19 knockdown inhibited proliferation, migration and invasion, and increased apoptosis, which was rescued by miR-15b inhibitor. H19 knockdown suppressed CDC42/PAK1 pathway and EMT progress. |
30543848
|
| miR-17 |
RNA-RNA |
regulation |
N/A |
LncRNA-H19, miR-17, and fibronectin constituted to a regulatory network involved in renal fibrosis. We also detected up-regulated H19 expression and down-regulated miR-17 expression in the early and advanced animal models of renal fibrosis. |
27391349
|
| miR-17-5p |
RNA-RNA |
binding |
N/A |
H19 antagonized the function of miR-17-5p on upregulation of its target YES1 and inhibited miR-17-5p-induced cell cycle progression |
27093644
|
| miR-17-5p |
RNA-RNA |
binding |
N/A |
H19 could directly target miR-130a-3p and miR-17-5p, thereby modifying the sensitivity of cardiac cancer cells to drugs and X-rays (P < 0.05). |
30843379
|
| miR-17-92 |
RNA-RNA |
binding |
N/A |
Mechanistically, we identified seven miR-17-92 cluster binding sites on H19, and found that H19 directly bound to miR-17-92 cluster via these seven binding sites. |
29143996
|
| miR-185-5p |
RNA-RNA |
binding |
N/A |
H19 directly targeted miR-185-5p, whereas miR-185-5p repressed IGF1 expression. |
31718549
|
| miR-18a-5p |
RNA-RNA |
binding |
N/A |
H19 can act as an endogenous sponge by directly binding to miR-18a-5p, which targets IRF2. |
30536700
|
| miR-18b |
RNA-RNA |
binding |
N/A |
lncRNA H19 directly interacted with miR-18b to regulate its expression. IGF1 was identified as a target of miR-18b. |
32265386
|
| miR-19 |
RNA-Protein |
binding |
N/A |
Silencing H19 greatly increased STAT3 expression by sponging miR-19 in vitro.H19 may serve as a competing endogenous RNA (ceRNA) to modulate STAT3 by attaching miR-17 in lung cancer.H19/miR-17/STAT3 axis participated in NSCLC development. |
29693721
|
| miR-193a-3p |
RNA-RNA |
binding |
western blot |
The lncRNA H19 was also found to directly target miR-193a-3p in inducing the HCC development. |
29968942
|
| miR-193b |
RNA-RNA |
binding |
N/A |
lncRNA H19 served as a sponge molecule to hijack miR-193b and protect MAPK1. |
31705929
|
| miR-194 |
RNA-RNA |
binding |
western blot |
The Effect of LncRNA H19/miR-194-5p Axis on the Epithelial-Mesenchymal Transition of Colorectal Adenocarcinoma |
30278464
|
| miR-194-5p |
RNA-RNA |
binding |
N/A |
H19 triggered autophagy via SIRT1 to induce cancer chemoresistance. miR-194-5p could directly bind to H19, suggesting H19 might work as a ceRNA to sponge miR-194-5p, |
30451820
|
| miR-196a |
RNA-RNA |
binding |
N/A |
H19 was a direct target of miR-196a and was associated with COL1A1 expression by sponging miR-196a. Moreover, downregulation of H19 alleviated fibroblast activation and lung fibrosis, and this effect was blocked by a miR-196a inhibitor. |
29411215
|
| miR-196b |
RNA-RNA |
binding |
N/A |
Mechanistically, miR-196b directly targeted LIN28B to inhibit LIN28B expression. H19 was capable of promoting LIN28B expression through sequestering miR-196b |
29950144
|
| miR-199a-5p |
RNA-RNA |
regulation |
N/A |
LncRNA-H19 enhanced MSCs survival and their angiogenic potential in vitro. It could directly upregulate VEGFA expression by inhibiting miR-199a-5p as a competing endogenous RNA. |
29673400
|
| miR-19a |
RNA-RNA |
binding |
N/A |
lncRNA H19 regulates the expression of ID2 through competitive binding to hsa-miR-19a and hsa-miR-19b |
28765931
|
| miR-19a |
RNA-RNA |
binding |
RIP |
we demonstrated the dual competitive interaction of miR-19a with H19 and the 3'-UTR of Id2 mRNA, resulting in the identification of the H19-miR-19a-Id2 axis. |
31170091
|
| miR-19a |
RNA-RNA |
binding |
western blot |
lncRNA H19 bound to micro ribonucleic acid (miR)-19a in a targeted way. |
31173326
|
| miR-19a-3p |
RNA-RNA |
binding |
luciferase reporter assay, western blot |
H19 regulated PI3K/Akt signaling through acting as a ceRNA for miR-19a-3p to target PTEN. |
32335212
|
| miR-19b |
RNA-RNA |
binding |
N/A |
lncRNA H19 regulates the expression of ID2 through competitive binding to hsa-miR-19a and hsa-miR-19b |
28765931
|
| miR-19b-3p |
RNA-RNA |
regulation |
western blot |
H19 overexpression significantly decreased cell proliferation and differentiation by down-regulating miR-19b-3p. |
31918667
|
| miR-200a |
RNA-RNA |
regulation |
western blot, RIP |
by using bioinformatics study and RNA immunoprecipitation combined with luciferase reporter assays, we demonstrated that H19 functioned as a competing endogenous RNA (ceRNA) for miR-138 and miR-200a, antagonized their functions and led to the de-repression of their endogenous targets Vimentin, ZEB1, and ZEB2, all of which were core marker genes for mesenchymal cells |
26068968
|
| miR-200a |
RNA-RNA |
binding |
N/A |
H19 regulated β-catenin expression and activity by competitively binding to miR-200a. H19 promotes cell proliferation by competitively binding to miR-200a and derepressing β-catenin in CRC. |
28164117
|
| miR-200a |
RNA-RNA |
binding |
N/A |
H19 sponged and inhibited miR-200a to de-repress expression of ZEB1 and ZEB2, and thereby enhanced lung cancer proliferation and metastasis. |
31187349
|
| miR-200a |
RNA-RNA |
regulation |
N/A |
we revealed that H19 exerted its effects by interacting with miR-200a in TGF-β-treated HTFs. |
31877306
|
| miR-200a-3p |
RNA-RNA |
binding |
N/A |
H19 regulated the proliferation and migration of CPCs through mediating the expression of Sirt1 which is a target of miR-200a-3p under hypoxia. |
30137188
|
| miR-203 |
RNA-RNA |
regulation |
N/A |
H19 negatively regulated miR-203. Inhibition of H19 attenuated miR-203 induced EMT process. |
30214583
|
| miR-20b-5p |
RNA-RNA |
regulation |
N/A |
Besides, H19 expression displayed a negative relationship to miR-20b-5p expression in endometrial cancer tissues. |
31411527
|
| miR-20b-5p |
RNA-RNA |
regulation |
N/A |
the knockdown of H19 slowed down tumor growth, promoted apoptosis and upregulated miR-20b-5p expression but lowered the expressions of HIF-1α, PCNA and AXL in vivo. |
31411527
|
| miR-21 |
RNA-RNA |
regulation |
N/A |
The combination of H19 and miR-21 may have diagnostic value in NSCLC and represent a target for new NSCLC treatments. |
28799568
|
| miR-21 |
RNA-RNA |
binding |
N/A |
lncRNA-H19 functioned via sponging miR-21 to facilitate PDCD4 expression and formed a competing endogenous RNA network (ceRNET) in ischemic cascade. |
31127201
|
| miR-216a-5p |
RNA-RNA |
binding |
western blot |
H19 regulates ACTA2 expression via competition for inhibitory miR-216a-5p binding sites. |
31323679
|
| miR-22 |
RNA-RNA |
binding |
RIP |
H19 functioned as an miRNA sponge for miR-141 and miR-22, both of which were negative regulators of osteogenesis and Wnt/β-catenin pathway. |
26853553
|
| miR-22-3p |
RNA-RNA |
binding |
N/A |
H19 was also found to be able to bind with miR‑22‑3p, and H19‑induced cell growth and metastasis were shown to be reversed by the upregulation of miR‑22‑3p |
31081061
|
| miR-22-3p |
RNA-RNA |
binding |
western blot, RIP |
mechanistically, miR-22-3p was a direct target of H19, |
31755219
|
| miR-22-5p |
RNA-RNA |
binding |
N/A |
H19 directly interfered with miR22-5p and miR675-5p expression, whereas the two miRNAs directly inhibited VDR expression. |
31887550
|
| miR-28 |
RNA-RNA |
regulation |
N/A |
LncRNA H19 down-regulated miR-28 expression, which in turn preventing SP1 from degradation by miR-28, and ultimately deactivated PDK/AKT and JAK/STAT signaling pathways. |
30312698
|
| miR-28 |
RNA-RNA |
regulation |
N/A |
miR-28 was negatively regulated by lncRNA H19, and SP1 was a target gene of miR-28 |
30312698
|
| miR-29a |
RNA-RNA |
binding |
luciferase reporter assay |
Bioinformatics analysis and luciferase reporter assay defined that H19 mediated the above effects via directly binding to miR-29a. |
27543358
|
| miR-29a |
RNA-RNA |
binding |
ELISA |
lncRNA H19 up-regulated the expression of TDG by repressing miR-29a because it acted as ceRNA through sponging miR-29a. |
31282110
|
| miR-29a |
RNA-RNA |
binding |
N/A |
H19 was capable of altering miR-29a expression within fibroblasts by directly sponging it, and overexpression of COL1A1 could deter the impact of miR-29a on viability, proliferation, migration, and invasion of fibroblasts (P < .05). |
31930556
|
| miR-29a |
RNA-RNA |
regulation |
N/A |
IGF-1 was a target gene of miR-29a and that H19 regulated IGF-1 expression via miR-29a. |
32084395
|
| miR-29a-3p |
RNA-RNA |
binding |
RIP, western blot |
A possible competing endogenous RNAs regulatory network involving lncRNA-H19 regulates E2F1 expression by competitively sponging endogenous miR-29a-3p in ccRCC. |
29214011
|
| miR-29a-3p |
RNA-RNA |
binding |
luciferase reporter assay, western blot |
It is bound to micro RNA (miR)-29a-3p in a targeted manner. |
31389605
|
| miR-29b |
RNA-RNA |
binding |
N/A |
We demonstrate that H19 is upregulated and miR-29b downregulated in individuals with DM and directly binds miR-29b. |
31737629
|
| miR-29b-3p |
RNA-RNA |
binding |
N/A |
H19 directly targeted miR-29b-3p and miR-29b-3p directly suppressed the expression of TGF-β1 and type I collagen to form a novel regulatory feedback loop between H19 and TGF-β1 to mediate tenogenic differentiation. |
27895107
|
| miR-29b-3p |
RNA-RNA |
binding |
N/A |
H19 was verified to directly target miR-29b-3p based on the luciferase reporter gene assay (P <0.05), and miR-29b-3p also bound to PGRN in a direct manner (P < 0.05). Finally, addition of LiCl (Wnt/β-catenin pathway activator) or XAV93920 (Wnt/β-catenin pathway inhibitor) would cause remarkably altered E-cadherin, c-Myc, vimentin and snail expressions, as well as significantly changed transcriptional activity of β-catenin/Tcf reporter plasmid (P < 0.05). |
29754471
|
| miR-29c |
RNA-RNA |
binding |
N/A |
H19 mediated the above effects by binding directly to miR-29c. |
30948500
|
| miR-30a |
RNA-RNA |
regulation |
N/A |
miR-30a negatively regulated H19 with each other through direct binding. |
31026067
|
| miR-3126-5p |
RNA-RNA |
regulation |
N/A |
H19 acting as a competitive endogenous RNA sequesters miRNA-3126-5p to reciprocally release ERβ expression. |
30389909
|
| miR-324-5p |
RNA-RNA |
binding |
N/A |
H19 directly bound to miR-324-5p. miR-324-5p directly targeted PKM2, and miR-324-5p negatively regulated glucose consumption and lactate production in ovarian cancer cells. |
30481782
|
| miR-326 |
RNA-RNA |
binding |
N/A |
The long ncRNA H19 on which a miR-326 putative binding site was found. |
30096248
|
| miR-342-3p |
RNA-RNA |
binding |
RIP |
H19 regulates FOXM1 expression by competitively binding endogenous miR-342-3p in GBC. |
27716361
|
| miR-342-3p |
RNA-RNA |
regulation |
western blot, ELISA |
LncRNA H19 over-expression suppressed Th17 differentiation and ESC proliferation through regulating miR-342-3p/IER3. |
31636893
|
| miR-370-3p |
RNA-RNA |
binding |
N/A |
Mechanistically, H19 could directly bind to miR-370-3p and effectively act as its competing endogenous RNA. |
29403287
|
| miR-372 |
RNA-RNA |
binding |
RIP |
H19 and HULC, up-regulated by oxidative stress, regulate CCA cell migration and invasion by targeting IL-6 and CXCR4 via ceRNA patterns of sponging let-7a/let-7b and miR-372/miR-373. |
27809873
|
| miR-373 |
RNA-RNA |
binding |
RIP |
H19 and HULC, up-regulated by oxidative stress, regulate CCA cell migration and invasion by targeting IL-6 and CXCR4 via ceRNA patterns of sponging let-7a/let-7b and miR-372/miR-373. |
27809873
|
| miR-612 |
RNA-RNA |
binding |
N/A |
MiR-612 could bind to lncRNA H19 and HOXA10. |
30070313
|
| miR-630 |
RNA-RNA |
binding |
N/A |
H19 regulated EZH2 expression by suppressing the activity of miR-630, which is a repressor of EZH2 and interacts with H19 in a sequence-specific manner. |
27040767
|
| miR-6515-3p |
RNA-RNA |
regulation |
N/A |
H19 may be an epigenetic regulator of miR-6515-3p, and its dysregulation may contribute to lung cancer progression and metastasis. |
31131469
|
| miR-675 |
RNA-RNA |
regulation |
western blot |
Ectopic expression of H19 significantly increased bladder cancer cell proliferation and miR-675 expression in vitro. |
26198047
|
| miR-675 |
RNA-RNA |
regulation |
N/A |
H19-derived miR-675 targeted at the 3'UTR of USP10, which resulted in the downregulation of p53 and p21 proteins. |
27062045
|
| miR-675 |
RNA-RNA |
regulation |
N/A |
PPARα was a target gene of miR-675 and that H19 negatively regulated PPARα expression via miR-675. |
30496976
|
| miR-675 |
RNA-RNA |
regulation |
N/A |
SPIF effects were mediated via the upregulation of lncRNA H19 and miR-675 and downregulation of let-7. sPIF also inhibited the expression of miR-21, a major fibrosis regulator. |
30692507
|
| miR-675 |
RNA-RNA |
regulation |
N/A |
expression of lncRNA H19 and miR-675 was up-regulated in patients with chronic hepatitis B (n = 20). Inhibition of lncRNA H19 or miR-675 in L02 cells increased cell viability, suppressed hepatitis B X protein (HBx)-induced cell apoptosis, inflammatory cytokine production, and oxidative stress, and remodelled energy metabolism. |
31574452
|
| miR-675-5p |
RNA-RNA |
regulation |
N/A |
Upregulation of miR-675-5p induced by lncRNA H19 was associated with tumor progression and development by targeting tumor suppressor p53 in non-small cell lung cancer. |
31219199
|
| miR-675-6p |
RNA-RNA |
binding |
N/A |
H19 directly interfered with miR22-5p and miR675-6p expression, whereas the two miRNAs directly inhibited VDR expression. |
31887550
|
| miR-874 |
RNA-RNA |
binding |
N/A |
H19 acted as AQP1 ceRNA in regulating miR-874 and restoring LPS dysregulated inflammatory responses and myocardial dysfunction. |
30021355
|
| miR-93 |
RNA-RNA |
binding |
western blot, ELISA, RIP |
MiR-93 interacted with either lncRNA H19 or XBP1s then modulating the inflammatory processes. |
31953562
|
| miR-93-5p |
RNA-RNA |
binding |
N/A |
H19 was a target of miR-93-5p. In addition, H19 antagonized the downregulation of miR-93-5p on its target STAT3 and antagonized miR-93-5p-mediated cell proliferation. |
30256448
|
| mTOR |
RNA-Protein |
co-expression |
N/A |
The results confirmed that knockdown of H19 inhibited mTOR and VEGF expression. In summary, the results indicate that H19 may be associated with increased proliferative activity of keloid fibroblasts, which may be mediated by mTOR and VEGF. |
27698867
|
| mTOR |
RNA-Protein |
regulation |
N/A |
PI3K/AKT/mTOR pathway might be involved in H19-mediated effects. |
31020694
|
| nucleolin |
RNA-Protein |
binding |
western blot, RIP |
an interaction between H19 and nucleolin was identified using the RNA-protein interaction studies. |
31975412
|
| nucleolin |
RNA-Protein |
regulation |
western blot, RIP |
Furthermore, H19 overexpression increased the stabilization of nucleolin; an interaction between H19 and nucleolin was identified using the RNA-protein interaction studies. |
31975412
|
| SAHH |
RNA-Protein |
binding |
N/A |
Metformin acts by upregulating microRNA let-7 through AMPK activation, leading to degradation of H19 long noncoding RNA, which normally binds to and inactivates SAHH. |
27775072
|
| STAT2 |
RNA-TF |
co-expression |
N/A |
The results showed that H19 overexpression was positively correlated with the expression of STAT2 and IRF9 and negatively correlated with the expression of miR-185-3p and others. H19 may participatein the regulation ADSC cartilage differentiation via the ceRNA-mediated STAT2 pathway. |
31191668
|
| sTLR4 |
RNA-Protein |
regulation |
N/A |
STLR4/MD-2 complex inhibits colorectal cancer migration and invasiveness in vitro and in vivo by lncRNA H19 down-regulation. |
29036538
|
| TDP43 |
RNA-Protein |
binding |
N/A |
H19 affected the differentiation of porcine satellite cells (PSCs) by directly binding to the DNA/RNA-binding protein TDP43. |
32121115
|
| VGF |
RNA-Protein |
binding |
western blot, RIP |
lncRNA H19 binds VGF and promotes pNEN progression via PI3K/AKT/CREB signaling. |
31117050
|
| YAP1 |
RNA-Protein |
co-expression |
western blot |
H19 expression was found to be significantly associated with YAP1 expression. H19, at least in part, is induced by YAP1 overexpression. |
26163939
|
| ZEB1 |
RNA-TF |
co-expression |
western blot |
The expression of H19 lncRNA and ZEB1 was positively correlated |
29559603
|